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Abstract

LENGTH OF HOSPITAL STAY, DELIRIUM AND DISCHARGE STATUS
OUTCOMES ASSOCIATED WITH ANTICHOLINERGIC DRUG USE IN ELDERLY
HOSPITALIZED DEMENTIA PATIENTS
By Kelly J. Gauthier, B.S.
A Thesis submitted ill partial fulfillment of the requirements for the degree of Master of
Science with a coi~centrationin Phamiacotherapy at Virginia Commonwealth University
Virginia Commonwealth University, 2006
Major Director: Dr. Patricia W. Slattum, Pharm.D, Ph.D
Assistant Professor and Geriatric Specialist
Department of Pharmacy

Problem: There are a significant proportion of patients taking acetylcholinesterase
inhibitors (ChEi) for cognitive dysfunction also taking medications with anticholinergic
(ACh) properties that may counteract their effects. As the number of ACh medications,
burden, increases so does the likelihood of an adverse outcome.

X

Background: ACh medications are frequently used in the elderly population (Carnahan
2004) even those with dementia or AD (Roe et al., 2002; Giron et al., 2001; Altavela 2003;
Gill et al., 2005; Kogut et al., 2005).
Methods: Hospitalized patients 2 65 years of age with dementia (AD, other dementias, or
with inferred dementia based on ChEi or NMDA antagonist medication use) were studied
using UHC clinical database. This document was created in Microsoft Word 2000.
Results: Dementia patients on ChEi therapy were more likely to receive an ACh (chisquare 70.1, df=l, p<.0001) and had a significantly higher ACh burden (p=.0017) during
hospitalization than those not on ChEi therapy.
Conclusion: A person's age and mental health status along with their current drug
regimen, such as ChEi therapy, need to be closely and carefully considered before deciding
to use unnecessary ACh drugs in this population which can have detrimental effects.

Chapter 1 Introduction

I. Introduction
Anticholinergic (ACh) medications are frequently used in the elderly population
(Carnahan et al., 2004) even those with dementia or Alzheimer's Disease (AD) (Roe et al.,
2002; Giron et al., 2001; Altavela, 2003; Gill et al., 2005; Kogut et al., 2005). Surveys of
administrative claims data from state Medicaid plans (Slatt~unet al., 2001 ; Carnaham et
al., 2004), found that 13.5% and 35.4% respectively of patients receiving cholinesterase
inhibitors (ChEi) were also receiving ACh drugs with significant central activity during a
3-month period.
The use of ChEi therapy has been associated with an increased risk of receiving an
ACli drug (Gill et al., 2005). Some patients may be prescribed an ACh medication or a
medication with ACh side effects to treat the side effects of ChEi therapy (Hashimoto et
al., 2000) such as those used to treat urinary incontinence (Roe et al., 2002; Gill et al.,
2005). Even the use of incontinence medications to treat overactive bladder (OAB) in
patients with AD, may have detrimental effects on mental status and behavior (Jewart
2005). Other drugs such as tricyclic antidepressants (TCA), antipsychotics (AP),
antispasmodics, antiparkinsons (benzotropine, trihexyphenidyl), antiarrhythmic
(disopyramide) and older-generation antihistamines (diphenhydramine,
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dimenhydrinate, chlorpheniramine) with known ACh activity are also frequently used in
AD patients. Most ACh medication use can be deemed as an inappropriate medication for
use in the elderly population (Agostini et al., 2001; Sloane et al., 2002; Fick et al., 2003;
Carnahan et al., 2004).
A number of studies have reported on the adverse effects associated with ACh
drugs in general elderly populations. A few studies have found elderly to be at risk of
cognitive impairment even at low serum ACh levels (Mulsant et al., 2003). Impairment of
self-care capacity and cognition have been found to be associated with high serum ACh
levels in dementia nursing home patients (Rovner et a1 1988). AD patients are at risk of
additional cognitive impairment from ACh drug therapy (Thienhaus et al., 1990).
The use of ACh medications or medications with ACh properties in communitydwelling elderly without dementia has been associated with lower cognitive performance
(Lechevallier-Michel et al., 2004; Ancelin 2006). AD patients have shown clinically
significant impairment of behavior and cognitive function (new learning and semantic
knowledge) at lower doses of centrally acting ACh medications, such as scopolamine,
compared to healthy, age-matched controls (Sunderland et al., 1987, 1988).
ACh load or burden is when there is more than one ACh drug or drug with ACh
properties co-administered. There are numerous studies which have shown ACh burden to
be a strong predictor of cognitive impairment (Golinger et al., 1987; Rovner et al., 1988;
Mach et a1.,1995; Mussi et al., 1999; Mulsant et al., 2003; Jeward et al., 2005; Chew et al.,
2005) and may be associated with excess disability in nursing home patients (Rovner et al.,
1988; Thienhaus et al., 1990). Tollefson et al., (1991), demonstrated that reducing ACh

load or burden can cause significant changes in short term memory, delirium, and
behavior. Even low ACh drug levels can cause mild but measurable cognitive impairment
in elderly patients (Miller et al., 1988; Sands et a1 1997).
Nishiyama et al., (1998), found a strong relationship between long-term exposure
to ACh medications and cognitive deficits with older Parkinson's disease patients. There
was also a significant association of chronic use of ACh medications (ie. 2 or more years)
with increased AD-type pathology in the frontal cortex, even though patients in the study
were not sufficiently symptomatic to warrant a diagnosis of dementia clinically (Perry et
al., 2003). A study by Lu and Tune found that chronic exposure of ACh therapy may be
associated with either detrimental effects on concomitant ChEi therapy or adverse effects
on the clinical course of AD (Lu and Tune 2003). In their study, AD patients taking ChEi
therapy and at least one ACh medication had similar decline in MMSE scores over two
years as AD patients who were not receiving ChEi therapy.
In hospital settings ACh medication exposure in older hospitalized patients has
been associated with an increased risk of cognitive decline, behavioral disturbances and
urinary catheter placement (Agostini et al., 2001; Han et al., 2001; Mulsant et al., 2004).
A dose-response relationship has been demonstrated with diphenhydramine and adverse
outcomes such as a significantly longer length of hospital stay and altered sleep-wake
cycle (Agostini et al., 2001). Han et al., (2001), showed that ACh exposure, independent
of initial severity of delirium or presence of delirium or other comorbid conditions, is
associated with the severity of delirium symptoms in hospitalized elderly patients with
diagnosed delirium.
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The prevalence of delirium in older hospitalized patients is 10-25% and has
significant hunian and economic burdens such as increased morbidity, a mortality of up to
40%, significantly increased hospital lengths of stay, institutionalization, and functional
disability (Thomas et al., 1988; Francis et al., 1990, 1992; Levkoff et al., 1992; Inouye et
al., 1993; Murray et al., 1993; Rockwood 1993). According to Francis et al., (1990),
approximately 40% of delirium cases in hospitalized elderly patients can be attributed to
medications.

11. Study Objectives
The specific aims of this study are:
To determine the prevalence of ACh use in hospitalized elderly patients with
dementia.
To determine the prevalence of ACh use in hospitalized elderly patients with
dementia on ChEi.
To compare the prevalence of ACh use between hospitalized elderly patients wit11
dementia on and not on ChEi therapy.
To compare ACh burden between hospitalized elderly patients with dementia on
and not on ChEi therapy.
To characterize prescribing patterns of ACh medications in the hospitalized elderly,
particularly those with dementia with or without ChEi therapy
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To compare the prescribing patterns of urinary antispasmodics, GI antispasmodics,
and ACh antispychotics between hospitalized elderly patients with dementia on and
not on ChEi therapy.
To evaluate and compare the impact of ACh medication use in hospitalized
dementia patients on length of hospital stay, discharge status, and having delirium
while in the hospital.
To evaluate and compare the impact of ACh burden in hospitalized dementia
patients on length of hospital stay (LOS), discharge status, and having delirium
while in the hospital.

111. Purpose and Significance
A. Purpose
The mainstay of AD treatment is through enhancing cholinergic neurotransmission
with ChEi. Cholinesterase inhibitor therapy is associated with significant cost for AD
patients. Giving other medications that block or counteract the potential benefits of this
therapy make those costs an unnecessary burden on the family and the health care system
as a whole.
The hypothesis guiding this research is that a significant proportion of patients
taking ChEi for cognitive dysfunction are taking medications with ACh properties that
may counteract their effects. As the number of ACh medications or ACh burden
increases, so does the likelihood of an adverse outcome.

B. Significance
No studies have reported on the ACh effects in hospitalized dementia patients. No
studies have examined whether the use of ChEi therapy in hospitalized dementia patients
taking ACh medication will have any effect on the adverse events associated with the use
of ACh medications. To date, there has been one study conducted in one hospital which
evaluated the use of one ACh drug, diphenhydramine, in hospitalized elderly patients.
This study will look at a clinical database with data on the use of numerous ACh
medications from 42 academic health centers from across the country. The descriptive
data obtained from this study will provide valuable information on the prevalence of
concomitant use of ACh and ChEi therapies. This study will provide information on the
adverse events associated with ACh use in dementia patients. It will also attempt to
provide some insight on the differences of ACh prescribing patterns between dementia
patients taking and not taking ChEi therapy.

Chapter 2 Literature Review

I. Alzheimer's Disease
A MedlineIPubmed search (time frame: up to January 2006) was performed to find
articles on the course, pathology, and prevalence of AD, the role of cholinesterase and
acetylcholine in AD, and the treatment of AD. Search terms used were: Alzheimer's
disease, acetylcholine and Alzheimer's disease, cholinesterase and Alzheimer's disease,
dementia, cholinergic receptor, muscarinic receptor, Alzheimer's disease treatment, and
cholinesterase inhibitors and Alzheimer's disease.
AD is a progressive neurodegenerative disorder and eventually leads to death. It
is the most common cause of dementia. A diagnosis of AD is not affirmative until death,
upon autopsy. Prevalence studies suggested that in 2000, the number of persons with
Alzheimer's disease in the United States was 4.5 million (Herbert et al., 2003). The
percentage of persons with Alzheimer's disease increases by a factor of two with
approximately every five years of age, meaning that 1 percent of 60-year-olds and about 30
percent of 85-year-olds have the disease (Jorm 1991). Without advances in therapy, the
number of symptomatic cases in the United States is predicted to rise to 13.2 million by
2050 (Herbert et al., 2003). The cost of caring for patients with Alzheimer's disease is

extraordinary, with annual expenditures totaling $83.9 billion (in 1996 U.S. dollars)
(Wimo and Winbald 2001).
There are three consistent neuropathological hallmarks in the pathology of AD:
amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. There are
many hypotheses on the pathology of AD and what causes these hallmarks. One
hypothesis is that the symptoms of AD result fiom the accumulation of beta-amyloid
peptide. Other hypotheses associate AD pathology with the hyperphosphorylation of Tau
protein, heavy metals, vascular factors, viral infections, and the loss of cholinergic
neurons.

A. The cholinergic hypothesis
The cholinergic hypothesis correlates the loss of acetylcholine activity, due to death
of neurons, with the severity of AD (Bartus et al., 1982). Compared to individuals without
AD, patients with AD demonstrate significant reductions in cholinergic activity in areas of
the brain (cortical and subcortical) important in the processes of memory and learning.
The changes in cholinergic activity are due to reductions in choline acetyltransferase
activity and number of cholinergic neurons in late AD, and selective loss of nicotinic
receptor subtypes in the hippocampus and cortex (Bartus et al., 1982; Whitehouse et al.,
1982; Guan et al., 2000).
These changes in the central cholinergic nervous system, both age- and diseaserelated, contribute to the functional decline, memory impairment, behavioral disturbances,
and worsening quality of life seen in AD. It has been demonstrated by numerous studies

that the extent of cholinergic loss in AD is correlated with the severity of cognitive
dysfunction and disease duration, as well as with the density of senile plaques of betaamyloid protein and intracellular neurofibrillary tangles (Perry et a1 1978; Bierer et al.,
1995; Bowen et a1 1982; Cumniings and Cotman 1995; Everitt and Robbins 1997).

B. Treatment of AD
Because of the functional outcomes of AD (functional decline, memory
impairment, behavioral disturbances, and overall worsening quality of life) and the fact
that there has been death of neurons, leads us to how AD is treated. In AD treatment only
the the symptoms are treated and not the disease itself.
The first treatment approach and currently the mainstay in mild to moderate AD is
the enhancement of cholinergic transmission with ChEi. ChEi enhances cholinergic
neurotransmission through inhibition of cholinesterase, the enzyme responsible for
hydrolyzing acetylcholine, in the central nervous system and therefore allowing
acetylcholine to remain in the synaptic cleft longer (Hogan and Patterson, 2002).
Maximizing cholinergic function may help patients maintain their ability to perform
activities of daily living (ADLs), temporarily slow cognitive decline/functional
deterioration, reduce emergence of behavioral disturbances, reduce caregiver burden and
defer placement in long term care (LTC) facilities (Cummings, 2004). Studies of ChEi
therapy show that there is a four to seven point improvement on the AD Assessment Scalecognitive proportion (ADAS-cog), a psychometric test, commonly used to establish
efficacy with respect to cognitive function.
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Maximizing the cholinergic system, also causes the common side effects of nausea,
diarrhea, and urinary incontinence through increasing activity at peripheral muscarinic
receptors. The actual incidence of urinary incontinence and how often ChEi therapy
worsens it are unknown.
A newer approach in the treatment of AD is memantine (Nemenda @), a N-methylD-aspartate antagonist approved for treatment of moderate to severe AD. Its benefits are
either through interfering with the glutamatergic excitotoxicity caused by beta-amyloid
peptide or its effects of symptomatic improvement on the hippocampal neurons (Parsons et
al., 1999). In clinical trials there were no clinically relevant differences between moderate
to severe AD patients in the memantine and placebo groups in terms of adverse events,
laboratory findings, electrocardiographic studies, or vital signs. When memantine was
administered to patients with moderate-to-severe Alzheimer's disease who were receiving
stable doses of a ChEi, cognitive improvement was seen as a reduced decline in ADLs and
a reduced frequency of new behavioral symptoms as compared with those receiving
placebo (Tariot et al., 2004). The magnitude of the improvements in patients in these trials
is modest, with improvement or temporary stabilization observed in daily function or
behavior.

11. Anticholinergics
A MedlineJPubmed search (time franie: upto January 2006) was performed to find
articles on ACh and their effects on the geriatric population (265), both demented and
non-demented, and their use in geriatrics. Search terms used were: anticholinergic,

anticholinergic and Alzheimer's disease, anticholinergic and cognitive function,
anticholinergic and dementia, anticholinergic and memory, anticholinergic and elderly,
anticholinergic and geriatric, anticholinergic and older persons, anticholinergic and side
effects, anticholinergic and urinary incontinence, treatment of overactive bladder, and
prevalence of anticholinergic and elderly.
ACh bind to muscarinic receptors to block acetylcholine actions and hence
decrease cholinergic neurotransmission. ACh medications are often used in the treatment
of movement disorders like Parkinson's Disease (benztropine, trihexyphenidyl), urinary
incontinence (tolterodine, oxybutynin, and the newer agents), dizziness (meclizine), and
insomnia (diphenhydramine). The common side effects of ACh are dry mouth,
disorientation, confusion, delirium, memory impairment, sedation, blurred vision, changes
in heart rate (bradycardia or tachycardia), urinary retention, and constipation.

A. Muscarinic receptors
There are two types of cholinergic (ACh) receptor systems: muscarinic and
nicotinic. There are at least five subtypes of muscarinic receptors (MI, M2, M3, M4, and
M5) which can be found distributed throughout the brain and (MI, M2, M3, and M4) in
different areas of the body. Areas of the body where the different receptor subtypes can
be found are listed in Table 1 on the following page.

Table 1. Locations of muscarinic receptor subtypes

1
M1

I

I

M2

M3
M4

MS

brain (cerebral cortex, hippocampus, & neostriatum), bladder,
salivary glands, sympathetic ganglia
brain (throughout), bladder, eyes, heart, smooth muscle
brain, eyes, smooth muscle, salivary gland, bladder
brain (neostriatum, cortex, hippocampus), bladder, salivary glands
brain (hippocampus & projection neurons of substantia nigra, pars
cornpacta, & ventral tegmental area), eyes (ciliary muscles)

I

I

All muscarinic receptor subtypes (MI-M4)are present in various regions of the
human brain. Of the receptor subtypes, MI is the most abundant in the cerebral cortex and
hippocampus, M2 are located throughout the brain, and Mj are located in low levels
throughout the brain. The muscarinic receptors of the brain are involved in several
processes including memory, learning, control of movement, nociception, and regulation
of circadian rhythm.
The cholinergic system exerts a major influence on the cognitive process, in
particular memory via MI cholinergic receptors as demonstrated through studies using
genetically modified (knockout) mice. Inhibition of the MI subtype in the brain is known
to disrupt cognitive functions such as learning and memory (Kay and Granville 2005).
Recent evidence suggests a role for M2 (Teaktong et al., 2005) receptors in mediating
cognitive function. Similar studies with knockout mice lacking M2 receptors show
significant deficits in behavioral tasks requiring working memory and dysregulation of
cholinergic function in the hippocampus, which are associated with cognitive deficits
(Lazaris et al., 2003). Other genetic studies have implicated a role for striatal M4
autoreceptors in the regulation of acetylcholine levels (Zhang W et al., 2002).
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Approximately two-thirds of the n~uscarinicreceptors of the bladder are M2 and
one-third M3. Both M2and M3muscarinic receptors facilitate contraction of the bladder,
but the M3 subtype is principally responsible for detrusor muscle contraction.

B. ACh and their use in urinary incontinence
New onset or worsening incontinence is commonly seen as part of the natural
history of dementia (Skelly and Flint 1995) and are highly prevalent and likely to occur
simultaneously in the elderly. Urinary incontinence occurs in approximately 33% of
women and 15-20% of men over the age of 65,50% of frail elderly or those over the age of
85 who have multiple comorbidities and at least 60-80% of residents of nursing homes or
skilled facilities receiving around the clock care (Jewart et al., 2005). Urinary incontinence
is not only common in fiail older adults, but has been associated with significant
morbidity, specifically premature nursing home placement (Thakar et al., 2000).
ACh agents such as oxybutynin, tolterodine, trospium, darifenacin, and solifenacin
(Table 2) are frequently used to treat overactive bladder in the elderly population and in
particular those with AD or Parkinson's disease (PD).

Table 2. ACh agents available for the treatment of OAB
Drug
Tolterodine (Detrol)

Formulation
IR
ER

Dosing
1,2 mg BID
2,4mg QD

chemical structure
nonlipophilic, tertiary amine

selectivity
nonselective

Oxybutynin (Ditropan)

IR
ER
skin patch

5mg BTID
5, 10, 15,20mg QD
3.4mgId every 3-4days

lipophilic, tertiary amine

M3, MI >>M2

Trospium (Sanctura)

IR

20mg BID
(at least one hr before food)

quaternary amine

nonselective

Darifenacin (Enablex)

CR

7.5, 15mg QD

tertiary amine

M3

Solifenacin (Vesicare)

CR

5,lOmg QD

tertiary amine

M3

IR: immediate release; ER: extended release; CR: controlled release; QD: once daily; BID: twice daily; BTID: 2-3 times daily

ACh agents currently used in the treatment of OAB have the potential to bind to
muscarinic receptors throughout the body, thereby mediating a variety of related adverse
events. There is growing evidence from different sources suggesting that treatment of
OAB with nonselective muscarinic antagonists may result in memory dysfunction (Tsao
and Heilman, 2003; Womack and Heilman, 2003), confusion and disorientation (Edwards
and O'Connor 2002) in the elderly population.
There are other factors that can affect a drugs capability to exert its effects on the

CNS by crossing the blood brain barrier (BBB). Factors that favor a medication's passive
penetration of the BBB include lipophilicity, a neutral charge, and a smaller, less bulky
molecular size. Trospiwn is the only quaternary amine used in the treatment of OAB. The
quaternary amine gives the trospium molecule a positive charge making it highly polar and
decreased lipophilicity and therefore is less likely to cross the BBB than the tertiary
mines. Its nonspecific effects are mainly seen in the periphery.
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Even though there are urinary incontinence medications that are receptor specific or
have a permanent charge to reduce its crossing of the BBB, there are still a number of
conditions that can increase the BBB permeability and therefore allowing drugs to cross
the blood brain barrier that would not have normally. These include being elderly (265),
use of certain medications, comorbid diseases and stress (Pakulski et al., 2000; Star et al.,
2003; Abdel-Rahman et al., 2004). The integrity of the BBB in those 65 years old and
older is unknown. Quaternary arnines have been shown to cross an intact BBB in animals
exposed to stress (Abdel-Rahman et al., 2004). There are also many comorbid conditions
that are common in older people that may make them more susceptible to cognitive
impairment and exaggerate the ACh drug effects on cognitive function (Doraiswamy et al.,
2002). Such conditions are type I1 diabetes mellitus, coronary artery bypass graft surgery,
cerebrovascular disease, Parkinson's disease, and AD and related dementias. In other
words, all ACh medications, regardless of their physiochemical properties, should be
considered to have the potential to cross the BBB.

C. Concomitant use of ACh and ChEi
There have been numerous studies that have looked at the prevalence of the
concomitant use of ACh and ChEi drugs. These studies are summarized in Table 3.
Studies by Carnahan and Roe found that approximately 35.4% of those on ChEi therapy
were also receiving at least one ACh, defined as ACh agents with clinically relevant ACh
properties from the Beer's criteria (Carnahan et al., 2004; Roe et al., 2002). Surveys of
administrative claims data from Medicaid plans found that 13.5-35% of patients receiving
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ChEi therapy were also receiving ACh drugs with significant central activity (Slattum et
al., 2001; Carnahan et al., 2004). Carnahan et al., (2004), was from January 1997 to
Febuary 2000. The use of ChEi therapy has been associated with an increased risk of
receiving an ACh drug to manage urinary incontinence (Gill et al., 2005).

Table 3. Published studies of the prevalence of concurrent ChEi & ACh
Authors, yr
Roe CM,
Anderson MJ,
Spivack B. 2002

Patient population

Study Design

Conclusionlfindings

n=836 (418 on
donepezil; 418 not on
donepezil therapy)

each member from ChEi group was
matched with a member from the
comparison group

rn

community-based
adults (>65)

used 3-12 months of pharmacy claims
data

rn

Camham RM,
Lund BC, et al.,
2004

n=557
Iowa medicaid
beneficiaries (150)

pharmacy claim for ChEi & ACh over
a 180d period, counted #ACh received
and timing (before or after ChEi
initiation)

rn

Gill SS, Mamdani
M, et al., 2005

n= 44884
study of older adults;
(n=20491) wl
dementia who
received ChEi
therapy
(n=24393) who didn't

-used administrative health care
databases of Ontario, Canada
-use of oxybutynin, tolterodine, or
flavoxate initiation of oxybutynin,
tolterodine, or flavoxate, for treatment
of urinary incontinence after ChEi
therapy is started

n=1183
(145) residing in the
community or LTC
facility dispensed a
ChEi

Use of developed list of drugs that can
impair cognition through review of
similar lists used by other researches

Kogut SJ, ElMaouche D,
Abughosh SM.
2005

rn

older adults wlprobable dementia were
more likely to use ACh.
In ChEi group, those receiving ACh: 33%
used 1 1 ACh med;
community-based, commercially insured,
older adults wlprobable dementia are
more likely to take ACh (TCAs,,
antipsychotics, UI drugs) than matched
controls.
35% of pts receiving ChEi also received
>1 ACh;
o those receiving ACh: nearly 75% were
considered as inappropriate for use in
elderly
of which 22% were deemed
inappropriate under any
circumstance.
ACh prescibing upon ChEi therapy
inception: cimetidine, ranitidine,
atropine, dicyclomine, hyoscyamine,
oxybutynin, & tolterodine
There was a significant increase in
receiving an ACh after initiation of ChEi
therapy; risk was same among the LTC
and community-dwelling settings
use of ChEi was associated with an
increased risk of receiving an ACh drug to
manage urinary incontinence
approximately 60% of patients taking
ChEi also received a drug that can impair
cognition

17
There are many reasons cited in the literature as to why ACh and ChEi should not
be used together. The American Psychiatric Association and the American Academy of
Neurology both have guidelines that reinforce the warning of the high risk of adverse
effects of ACh drugs given to patients with dementia.
Chronic exposure to ACh medications can adversely affect the course of AD (Lu
and Tune 2003). In a two year retrospective study in 69 patients diagnosed with probable
AD and receiving donepezil, patients were divided into two groups based on the number of
ACh medications they were concomitantly taking. Sixteen subjects received at least one
ACh medication and 53 were not taking any ACh drugs concomitantly. Patients took an
annual Mini Mental State Examination (MMSE) and had blood drawn for the serum
anticholinergic activity (SAA) radioreceptor assay. They found that those patients that
were receiving ACh drugs showed a significantly greater decline, an average decline of 7
points over 2 years, in MMSE scores than those who were not taking ACh drugs, average
decline of 3 points over 2 years. Those that were taking ACh conconlitantly experienced
similar declines in their MMSE scores as patients who do not take ChEi therapy (average
decline of 3.5 points per year) (Burns et al., 1991). The findings suggest that concomitant
treatment with ACh drugs may be associated with significant deleterious effects on ChEi
therapy or that chronic exposure to ACh may have adverse effects on the clinical course of
AD.
Studies by Sunderland et a1 and Agnoli et al., have shown that the addition of
medications with ACh properties may diminish any potential benefits from ChEi and
possibly exacerbate cognitive decline in AD patients (Sunderland et al., 1987, 1988;
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Agnoli et al., 1983). AD patients are at risk of additional impairment from ACh drug
therapy (Thienhaus et al., 1990). In an observational study in geropsychiatric inpatients,
ten with probable AD and 18 without significant impairment, participants were subject to a
battery of cognitive tests and had their SAA measured. Non-demented subjects were
significantly less vulnerable to the cognitive effects of ACh drugs than were the demented
patients. The implication being that ACh drugs may be associated with excess disability in
geriatric inpatients. There have also been case reports of delirium with oxybutynin and
tolterodine in patients that were also concomitantly taking ChEi therapy (Edwards et al.,
2002)

D. ACh and Delirium
ACh medications are a well-known cause of delirium most likely due to a direct
reduction in central cholinergic activity. N~mierouschallenge studies have found
impairments in various aspects of cognitive function after administering standard
therapeutic doses of ACh medications to normal healthy adults (Mulsant et al., 2003;
Rovner et a1 1988; Katz et al., 1998; Lechevallier-Michel et al., 2004; Ancelin 2006).
The results of the Sunderland et al., study suggest that dementia may modify the
ACh-deliriuni relationship. Their study, patients with dementia showed significant
cognitive decline at doses of ACh medications at which their non-demented controls did
not (Sunderland et al., 1987).
Cholinergic antagonistic binding at these muscarinic receptors can further impact
dementia and cognitive deficits in patients with dementia of Lewy bodies (DLB), which
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accounts for 15-25% of dementia in the elderly (Teaktong et al., 2005), and those with
Alzheimer's disease (AD). Therefore current data suggests that cognitive impairment, in
particular memory dysfunction, could result fiom antagonism of MI and to some extent M2
and M4 receptors in the CNS. Thus, older patients with existing cognitive impairment,
especially those with early-stage dementia, age-associated memory impairment, or mild
cognitive impairment may be especially vulnerable to these cognitive side effects.
Numerous studies have noted an association between medications with ACh
properties and delirium. Table 4 summarizes studies on ACh drug use and their
association with delirium. Even though this syndrome has long been recognized, the full
extent of its nature is not yet fully understood. The ACh effects of many drugs and their
metabolites are unknown and since most elderly patients take a number of medications, it
is difficult to discern what their ACh burden is, thus there needs to be a method for
measuring or assessing one's ACh burden.

Table 4. Published studies: ACh and delirium
Authors, yr

Tune LE, et al., 1981

Patient population
n=29
cardiac surgery pts
(29-75 yo)

Definition o f Ach drug
o r burden & delirium
meaurement

ConclusioniFindings

10 delirious pts
19 control pts

delirium was significantly associated with SAA.
higher SAA was associated with lower MMSE

Golinger RC, Peet T,
Tune LE. 1987

n=16
surgical ICU pts.
(29-76 yo)

Plasma AA & drug-risk
number

Plasma AA was signifiicantly higher in the
delirious pts (ave age=60) than in the pts wlo
delirium (ave age=57).

Francis et al., 1990

n=229
community-dwelling
elders admitted to
medical ward (> 70)

MMSE, DSM-111 and
noted if pt had taken an
ACh

ACh drug use was not associated with delirium.

Schor et al., 1992

n=29 1
general and medical ward
pts (165)

DSM-111 and counted
number of doses received

Delirium not significantly associated with ACh
drug use

(Table 4 continued from pg 19)

Authors, yr

1

Patient population

Definition of Ach drug
or burden & delirium
meaurement

Conclusion/Findings

Tune LE, et al., 1993

n=25
surgical ICU pts (29-74
YO)

SAA & DSM-I11

Significant relationship between SAA and
delirium.

Marcantonio et al.,
1994

n=91
surgical pts

MMSE, CAM, and
counted number of doses
received

Delirium not significantly associated with ACh
drug use

Mach JR, Dysken
MW, et al., 1995

n=12,
male delirious & nondelirious pts (> 60)
case-control study.&
with-in subjects repeatedmeasures in recovered
delirious pts

SAA

mean SAA was significantly elevated in delirious
group vs non-delirious group

Flacker JM, et al.,
1998

n=67 medical ward pts 2
75 yo

20 delirious patients vs 47
non-delirious patients

SAA was associated with delirium in a
multivariate analysis

Flacker JM, Lipsitz
LA. 1999

n=22 NH residents

8 delirious pts
14 non-delirious pts

SAA appears to be elevated during illness, and
declines following recovery from illness and not
associated with delirium.

Mussi C, Ferrari R, et
al., 1999

n=61; elderly pts (166
yo) admitted to hospital

divided into 2 groups
based on presence (n=12)
or absence (n=49) of
delirium
yo= years of age; pts= patients; AA= ACh activity; BZ= benzodiazepines

high levels of SAA were significantly correlated
with delirium

111. Delirium and Adverse Outcomes
A MedlineIPubmed search (time frame: upto January 2006) was conducted to find
articles on delirium and its effects on the geriatric population (265), and the frequency of
delirium occurrence and adverse outcomes associated with developing delirium during
hospitalization in the elderly. Search terms used were: delirium and geriatric, delirium and
elderly, delirium and older persons, delirium and hospitalization, delirium and morbidity,
and delirium and mortality.

I
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Delirium is defined as an acute disorder of attention and cognition and occurs in
14-56% of hospitalized elderly patients (Rosin and Boyd 1966; Chisholm et al., 1982;
Gillick et al., 1982; Levkoff et al., 1992; Inouye et al., 1993). Delirium has been
associated with several adverse outcomes such as increased rates of morbidity, mortality
and institutional placement, and with loiiger, costlier hospitalizations (Weddington 1982;
Thomas et al., 1988; Rockwood 1990; Levkoff 1992). Mortality rates of 12-76% have
been reported (Weddington 1982; Lagoe RJ 1986; Thomas et al., 1988).
In a prospective study by Francis et al.,, participants in the study were 70 years or
older, admitted directly to the medical ward from the community and underwent evaluation
within in 48 hours of admission. The evaluation included an interview, chart review,
MMSE, an assessment of ADL, and Blessed's Dementia Rating Scale. Patients were
followed up on six months after discharge by phone. Patients who developed delirium
stayed an average of 12.1 days longer in the hospital than those who did not. They also
were 8% more likely to die or 16% more likely to be institutionalized compared to those
who did not develop delirium (Francis et al., 1990).
Medical comorbidity and predisposing, as well as precipitating, factors are
important to consider in the management of delirium. Major risk factors for delirium
include advanced age, cognitive impairment, and chronic medical illness (Williams et al.,
1985; Foreman 1989; Francis et al., 1990; Schor et al., 1992).
Schor et al., calculated incidence of delirium and risk factors for delirium in elderly
hospitalized patients. Patients in their study were 65 years or older admitted from either a
rehabilitation center for the aged or the community. Diagnosis for delirium was based on

Diagnostic and Statistical Manual of Mental Disorders, third edition (DSM-111). In the
Schor et al., study nearly one third of the 325 patients who participated developed
delirium. Patients who developed delirium had a mean length of stay of 18.8 days vs 13
days in those who did not develop delirium (Schor et al., 1992). Almost 50% had met the
DSM-I11 criteria for delirium by day 3 and 91% by day 7 of their hospital stay. Admission
risk factors found to be strongly predictive of delirium were age greater than 80, prior
cognitive impairment, fracture on admission, and institutionalization prior to admission.
Levkoff et al., evaluated the occurrence and persistence of delirium in 325 elderly
patients admitted to a teaching hospital from either the community or LTC facility. On
admission approximately 11% met DSM-I11 criteria for delirium and of the remaining
patients nearly one third developed new onset delirium during their hospitalization. Risk
factors identified in this study for the development of delirium were preexisting cognitive
impairment and advanced age. Increased risk of developing delirium was seen in those
admitted from the comnlunity and not from institutions. They also found delirium to be
associated with prolonged hospital stay and an increased risk of institutional placement
among the community dwelling but not an increased risk of mortality (Levkoff et a1 1992).

IV. Assessing ACh burden
ACh burden refers to the cumulative effect of taking multiple drugs with ACh
activity. A MedlineIPubmed search (time frame: upto March 2006) was conducted to find
all articles that used ACh burden as a predictor of delirium in elderly individuals to see
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how ACh burden was calculated and defined. Search terms used were: anticholinergic
burden, serum anticholinergic activity, anticholinergic activity, and anticholinergic effects.
There are four general methods for measuring ACh burden they are: measurement
of total SAA resulting from drugs, metabolites, and patient physiology; ACh drug lists
combined with clinical judgement; measurement of individual drug-related ACh activity;
and measurement of individual muscarinic receptor affinity in vitro. Sometimes these
methods are combined.

A. Serum Anticholinergic Activity
One commonly used method for measuring ACh burden is by measuring the SAA.
SAA was first described by Tune and Coyle (1980) to quantify the ACh burden of drug
exposure. The assay is performed by incubating a small amount of sample solution of an
ACh in a phosphate buffer containing [3~]quinuclidinylbenzilate (QNB), a potent
muscarinic antagonist, and a suspension of rat striatal membranes, which are rich in
muscarinic receptors. The ACh substances in the sample competitively inhibit the binding
of the radioactively labeled QNB to the receptors to a degree determined by their
concentrations and affinity for these receptors. In other words, it measures the binding
affinity, ACh potency (the higher the binding affinity the greater the ACh potency) of ACh
drugs and also of non-ACh drugs that exhibit ACh-like properties such as TCA. The
binding affinity is usually measured in atropine equivalents so that comparisons may be
made across different drugs. SAA has been used in many studies and has been found to be
associated with mental status changes in a number of clinical settings and patient
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populations. Table 5 summarizes all of the published studies reviewed on the relationship
of SAA and cognition.
SAA was measured in postoperative cardiac patients from 29-75 years of age (Tune
et al., 1981). Elevated levels were significantly associated with an increased risk of
delirium and reductions in scores on the MMSE correlated with SAA levels (p < .001).
Another study (Golinger et al., 1987) looked at surgical patients in the ICU ranging from
25-76 years of age and found that mean SAA was significantly greater in delirious patients
than in nondelirious patients (p < .05).
Flacker et al., 1998, found an association between higher SAA levels with delirium
in 67 medical inpatients over 75 years of age (p = .006). The patients SAA levels were put
into quintiles, 1 being the lowest and 5 the highest levels. The prevalence of delirium
increased steadily from 7.7% in the first quintile to 6 1.5% in the fifth quintile.
In another study by Flacker et al., 1999, SAA, MMSE, and the delirium symptom
interview were measured in 22 nursing home residents during a febrile illness and then
again at one-month follow-up. Those in the delirious group had higher Cognitive
Performance Scale scores, indicating more impairment, than those that were not delirious
(p < .01). SAA in this study was not significantly different between the groups at baseline
or at follow-up.
In a study for risk factors for delirium in patients admitted to a geriatric medical
ward, Mussi et al., 1999 found that elevated SAA levels were independently associated
with the presence of delirium (p < .004) along with antipsychotic use (p < .002) and
benzodiazepine use (p < .005).
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Rovner et al., 1988, studied the relationship between SAA levels and self-care
capacity in 22 demented nursing home patients. Those patients that had SAA levels above
the median SAA displayed significantly greater impairment in self care than did patients
below the median (p = .03).
Miller et al., 1988, evaluated cognitive function in relation to SAA in presurgical
patients over the age of 59 and showed that even low SAA levels can significantly impair
patient's performance on cognitive testing. Cerebrospinal fluid ACh activity was
measured in nine patients who received spinal anesthesia and was found to be significantly
correlated with SAA (p<.05).
Thienhaus et al., 1990, studied SAA effects in geropsychiatric inpatients with
probable AD compared to patients without cognitive impairment. In the probable AD
patients there was a significant increase in SAA with the implemented drug therapy and
SAA was significantly associated with worsening on a number of cognitive measurement
scales. This same finding was not found in the patients without cognitive impairment
suggesting that demented patients may be more susceptible to the detrimental cognitive
effects of ACh medications than nondemented patients.

Table 5. Published Studies: Relationship between SAA and cognition
Authors, yr
Tune LE, et al.,
1981

Patient Population
n=29
cardiac surgery pts
(29-75 yo)

Study Design
10 delirious pts
19 control pts

Outcome Measure@)
SAA

Mondimore FM et
al., 1983

post-ECT pts
(17-76 yo)

pts treated with
atropine

SAA and MMSE

Conclusion/ Findings
-delirium was significantly
associated with SAA.
-higher SAA was associated with
lower MMSE
higher SAA levels associated with
decrease in MMSE

(Table 5 continued from page 25)
Authors, yr
Golinger RC, Peet
T, Tune LE. 1987

Patient Population
n=16
surgical ICU pts
(29-76 YO)

Study Design
9 delirious pts
16 non-delirious pts

Outcome Measure(s)
plasma ACh activity
MMSE
calculated drug-risk

Conclusion/ Findings
plasma ACh significantly higher
in the delirious pts than in the pts
without delirium

Miller PS,
Richardson JS, et
al., 1988

n=36
presurgical elderly
pts (>59 yo)

Scopolamine (n=14)
placebo (n=16)

SAA & CSF ACh levels;
mental status battery test
(RAVL).

low ACh drug levels can cause
mild but measurable cognitive
impairment in elderly pts.

Rovner BW,
David A, et al.,
1988

n=22
demented NH pts

All residents with
cognitive impairment

MMSE; SAA

Thienhaus, Allen,
et al., 1989

n=28
geropsychiatric
inpatients

probable AD (n=10)
compared to pts
without significant
cognitive impairment
(n=18)

MMSE, Digit Retention
Span, word recognition,
category retrieval, Selfrated Memory Scale
(SRM); SAA

Tollefson GD,
Montague-Couse
J, Lancaster SP.
1991

n=34; NH residents
165~0
receiving 21 ACh
medicine

15 intervention pts
19 control pts

SAA; battery of
Psychometric testing

-SAA levels were related to
cognition & capacity for selfcare.
-high ACh levels associated with
greater impairment in self-care
capacity than pts with low levels
-non-demented subjects were
significantly less vulnerable to
cognitive effects of ACh than
demented pts
-cognitive performance decreased
as ACh load increased
reducing ACh load gave a
lowered SAA and was
significantly related to improved
cognitive performance

Tune LE, et al.,
1993

n=25
surgical ICU pts
(29-74 yo)

9 delirious pts
16 control pts

SAA & DSM-111

Significant relationship between
SAA and delirium.

Mach JR, Dysken
MW, et al., 1995

n=12
> 60 yo male
delirious & nondelirious pts
n=36;
geropsychiatric pts,
mean age of 69

11 delirious pts
11 control pts

SAA

Resolution of delirium was
associated with decrease in SAA

17 with undetectable
SAA; 19 with
detectable SAA

SAA

detectable SAA was associated
with lower cognitive performance

n=67
medical ward pts
( r 75)
n=22
NH residents

20 delirious patients vs
47 non-delirious
patients

SAA & Delirium
symptom interview

SAA was associated with delirium
in a multivariate analysis

8 delirious pts
14 non-delirious pts

Cognitive performance
scale (CPS); SAA

SAA appears to be elevated
during illness, and declines
following recovery from illness
and not associated with delirium.

Mussi C, Ferrari
R, et al., 1999

n=61; elderly pts
( 1 66 yo) admitted
to hospital

CAM for presence of
delirium; SAA

high levels of SAA were
significantly correlated
wldelirium,

Mulsant BH,
Pollock BG, et al.,
2003

n=201; community
study based on age
& sex ( 1 65)

divided into 2 groups
based on presence
(n=12) or absence
(n=49) of delirium
21 pts with
undetectable SAA
159 pts with low SAA
21 pts with high SAA

cognitive performance:
MMSE; SAA

2 strongest predictors of cognitive
imprt: MMSE & ACh load. Ach
load was a very strong predictor
in degree of cognitive
impairment, even low SAA was
associated with cognitive
impairment.

Chew ML,
Mulsant BH, et al.,
2005

n=26;
geropsychiatric
inpts treated for
behavioral disturbx
assocd wldementia

Baseline SAA

cognition: MMSE &
severe impairment
battery; SAA

in patients with moderate-severe
dementia- higher SAA assocd
with lower cognitive performance

Nebes RD, et al.,
1997
Flacker JM, et al.,
1998
Flacker JM,
Lipsitz LA. 1999

pts: patients; yo: years of age; SAA= serum ACh activity; d/o=disorder

The advantage to this method is that it has been shown in numerous studies to be
related to cognitive impairment or improvement. Limitations to this method of measuring
ACh burden are that it is an invasive procedure which requires blood samples to be drawn.
Also, it is not a commercially available test and it doesn't provide a basis on which to rank
the contribution of ACh activity from individual drugs and therefore limits its use in
clinical practice and research studies.

B. ACh drug lists combined with clinical judgment
There are several subjective and objective published developed lists (Flacker et al.,
1998; Mintzer 2000; Tune 2001; Miller 2002; Roe et al., 2002; Mulsant et al., 2003; Mann
et al., 2003; Defilippi 2003; Scheife et al., 2005) available that can be used in combination
with clinical experiences, to rate the ACh activity of the drug in question. Table 6
summarizes all of the published lists.
The subjective assessment relies heavily on clinician knowledge of physical and
cognitive impairments associated with ACh drugs. The objective approach makes use of
physical or cognitive rating scales to quantify drug-related ACh effects, for example AIMS
(the Abnormal Involuntary Movement Scale). Other types of published lists that have
been developed are those based on clinican experience and objective measures. An
example of this would be the Beer's criteria, which is a list of drugs which should be
avoided in the elderly (Beers 1997; Fick et a1 2003).
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The advantage to using this method is that it can serve as an aid or a guide to help a
clinician decide the degree of risk an ACh drug may pose for an individual. The
limitations are that it depends on the clinician's perspective, knowledge, and experience.
The list must be combined with clinical judgement and then applied to each practice
setting. There is no standardized, comprehensive ACh drug list available. Even with the
combination of clinical tools such as the MMSE, which is not sensitive enough to detect
mild drug-induced cognitive changes produced by ACh drugs, other tools such as the
AIMS test have not been validated to ensure accuracy in detecting physical changes due to
ACh drug reduction or discontinuation.

Table 6. Drugs with Definite or Possible ACh effects

I

DEFINITE EFFECTS:
GI: atropine, belladonna alkaloids, clinidium-chlordiazepoxide, dicyclomine, diphenoxylate,
Antispasmodics
hyoscyamine, scopolamine
urinary: oxybutynin, tolterodine
muscle: carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine

1

Antidepressants

TCA (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline)

I

Antipsychotics
Antiparkinsons

olanzapine, perphenazine, promazine, thioridazine
benztropine, trihexyphenidyl

Antihistamines

chlorpheniramine, cyproheptadine, dcxchlorphcniramine, diphenhydraminc, hydroxyzine, meclizine

I

I
1

Antiemctics
dimenhydrinate, prochlorpcrazine, promethazine, uimethobenzamide
Benzodiazepines
alprazolam, clorazepate, ehlordiazepoxide, diazepam, flurazepam, oxazepam
Cardiovascular
disopyramide, procainarnide
POSSIBLE EFFECTS:
Antipsychotics

I

Antidepressants
Antidiarrheal
Cardiovascular
Miscellaneous

chlorpromazine, clozapine, fluphenazine, haloperidol, olanzapine, quietapine, risperidone,
thiothixene, trazodone,
SSRIs (escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline)
diphenoxylate
captopril, digoxin, dipyridamole, doxazosin
codeine, prednisolone, prednisone

Adapted from references: Flacker et al., 1998; Mintzer 2000; Tune 2001; Miller 2002; Roe et al., 2002; Fick et al., 2003; Mulsant et al., 2003; Mann et al., 2003;
Defilippi 2003; Scheife et al., 2005
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C. Measurement of individual drug-related ACh activity
This method also uses the radioreceptor assay but in vitro (use of a standard
concentration of a drug instead of patient's serum) to identify the ACh activity of
individual drugs (Tune et al., 1991, 1992, 1993, 1999,2000). Many of these studies have
looked at drugs that are commonly used in the elderly.
The advantage to using this method is that it allows for the direct comparison of
ACh activity of different drugs using atropine equivalents. The higher the atropine
equivalent the more likely the drug will express ACh properties. One drawback is it does
not account for varying drug dosages, pharmacokinetics, or differences due to individual
patient physiology. Another limitation is that standardized drug concentrations may not
reflect the concentration achieved at physiological conditions, nor of metabolites or the
effects of protein binding.

D. Measurement of individual muscarinic receptor affinity in vitro
This method focuses on the drug-receptor interaction through direct measurements
of receptor affinity by comparing the competitive binding between a radiolabeled
muscarinic-cholinergic agonist and a study drug with muscarinic ACh receptor.
It could be used clinically to compare the relative differences in muscarinic
receptor affinity as an indicator of a drug's ACh activity. The limitations of this method
are that a drug's ACh activity is relative to the drug concentration necessary to produce
50% binding inhibition of a radiolabeled cholinergic agonist. There is also very limited
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published data of dissociation constants for many drugs, which limits the utility of this
approach.

E. Combination
There has been some research done using a combination of the above methods to
measure ACh burden, each combination different from the other. One attempt to bring
clinical utility to SAA is through using it to validate an ACh scale that can be used in
practice to assess ACh burden (Carnahan et al., 2002). Carnahan et al., modified the
original ratings of the Clinician-rated ACh scale (Han et al., 2001) only if there was
compelling evidence such as receptor binding studies or clinically documented ACh effects
to warrant the change. They then used SAA to validate the modified version (mCr-ACh
scale) to assess ACh burden. The mCr-ACh scale rates the ACh nature of each medication
on a scale of 0-3; 0 has no known ACh properties, 1= potentially ACh as evidenced by
receptor binding studies, 2 = ACh effects sometimes noted but usually from excessive
doses, and 3 = markedly ACh. Scores of the individual drugs taken by study participants
were summed to determine their ACh burden. They found significant correlation between
SAA and the mCr-ACh scale but the scores only explained a small variance in the
observed SAA among the study participants which could be due to some of the limitations
of this method. A limitation to the mCr-ACh scale is that it does not allow for differences
in dosages nor take into account the differences in subject pharmacokinetics. By lumping
ACh drugs into general categories it assumes that they are equally ACh when in fact this is
most likely not the case. Another limitation is in the calculation of the burden score, by
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summing the scores it assumes that two drugs each with a rating of two would be equally
ACh to one drug with a rating of 4.
Another approach that has been used is to multiply the atropine equivalent for a
particular drug, as determined by antimuscarinic radioreceptor assay, by the total daily
dosage and then sum the products to generate an ACh score (Tune et al., 1981, 1992;
Francis et al., 1990).
Another method is to take the class of the drug and multiply it by daily effective
dosage level number to give a drug risk number (Summers 1978). This method also
attempts to classify drugs by their ACh properties or effects and assigns them a number (13). The class of drug was classified as class I- known synergistic effect with ACh agents,
but not known as a direct cause of acute organic mental syndrome; 11- known to cause
delirium, but currently not documented to have CNS ACh properties; 111- known to cause
delirium reversed by CNS active anticholinesterases or known to have CNS ACh effect
and to cause delirium. It then defines daily effective dosage based on a therapeutic dosage
range given over a 24 hour period and assigns the dose a number. The criteria for daily
effective dosage was defined as dosage level I- that dose range which would not give
therapeutic effect for a 24 hour period; 11- dose range which gives a therapeutic effect for a
24 hour period; 111- dose range which exceeds the usual therapeutic range for a 24 hour
period. It is these two assigned numbers that are multiplied together to calculate the drug
risk number.
Schor et al., 1992, used a different approach for assessing ACh burden. In this
study they used hospital admission records and counted each dose given, so that the tallied
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number, indicating the total number of ACh drugs received by the patient, was equal to the
total number of doses given. The limitation of this method did not take into account ACh
exposure, dose exposure nor ACh binding affinity.
Marcantonio et al., 1994, studied dose response effect of benzodiazepines and ACh
drugs and delirium in postoperative patients. They classified ACh exposure as either low
or high depending on dose administered and whether or not it was given in single or
multiple doses. The limitations with this method are it only looks at dose exposure, it does
not take into account ACh potency or binding affinity.
Cao et al., 2006, in their calculation of ACh burden, normalized ACh exposure by
taking the ACh dose given and dividing it by the sum of the ACh dose given with the
minimum recommended daily dose.
In summary, there is not one standardized or universal method of measuring ACh
burden. There have been multiple approaches and each has positive and negative
characteristics. Finding a method that contains all of the positive characteristics of these
methods and eliminates potential areas of subjectivity and has clinical utility would be
ideal, but much research is still needed to create an ideal method of assessing ACh burden
for clinicians caring for the geriatric population.

CHAPTER 3 Methodology

I. Subjecflatient Definition
A. Population
Hospitalized patients > 65 years of age that have documented dementia as defined
by ICD-9 codes (Appendex A) or inferred dementia based on use of drug therapy used in
the treatment of dementia (Appendix A) during hospitalization were studied. This
evaluation was conducted using the university Health System Consortium (UHC)
Clinical Database. The UHC is an alliance of 90 academic health centers in the US. The
UHC Clinical Database (CDB)-Pharmacy database contains a comprehensive collection
of procedure and diagnoses-specific data derived from discharge abstract summaries and
UB-92 data, coupled with specific medication use from charge transaction masters and
patient billing files for all inpatients at participating (currently 42) centers. UHC maps
members' charge transaction masters (CTM) drug descriptions into a common pharmacy
lexicon, standardizing descriptions to achieve reporting at the fundamental drug level.
Four quarters (12 months) of data was evaluated from October 2003 to September 2004.
Data was available for this analysis through a data use agreement between Virginia
Comnlonwealth University (VCU) and UHC. The data collection, analysis and reporting
was consistent with this agreement and compliant with HIPAA privacy provisions. No
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individual patient identifiers were maintained in the study data set to preserve patient and
health system confidentiality. This study was reviewed by the VCU Office of Research
Subject Protection Institutional Review Board and found to qualify for exemption from
federal regulations requiring IRB review and approval. No safety reporting was
performed because the study is a retrospective analysis of a dataset that does not contain
individual patient and health system identifiers.

B. Sample Size
There are 12,481 hospitalized elderly patients > 65 years of age with dementia. Of
the 12,481 hospitalized elderly patients, 6926 were on ChEi therapy.

11. Study Design and Data Collection
A. Design
This study is a prevalence survey of ACh medication (Appendix B) use in a
hospitalized setting in individuals 2 65 years of age with dementia on or not on ChEi
therapy. Those on a ChEi and an ACh were compared to those on a ChEi and no ACh.
Another comparison made was between those on an ACh and a ChEi to those on an ACh
and no ChEi.

B. Data Collection
Patients 2 65 years of age in the database were subdivided into two mutually
exclusive groups: 1) patients on ChEi therapy or NMDA therapy (Appendix A) use

35
during hospitalization and not receiving ACh (Appendix B), and 2) patients on ChEi or
NMDA therapy (Appendix A) use during hospitalization and receiving ACh (Appendix B).
The total number of patients in each group was determined. ACh medication use was
determined for each patient in each group. The following ACh medications with central
nervous system activity were included in this review (Piecoro et.al., 1998; Semla et.al.,
2001): tricyclic antidepressants (amitriptyline, doxepin, imipramine, nortiptyline,
desipramine), sedating antihistamines (diphenhydramine, promethazine, hydroxyzine),
antiparkinson's drugs (benztropine, trihexyphenidyl), urinary antispasmodics (oxybutynin,
tolterodine), gastrointestinal antispasmodics (atropine, scopolamine, hyoscyamine,
belladonna alkaloids, dicyclomine), or antipsychotics (AP) (chlorpromazine, clozapine,
promazine, thioridazine, olanzapine). The average dose per days of therapy and days of
therapy for each centrally-acting ACh prescribed, length of stay (outcome measure), and
potential confounders: age, sex, race, presence of delirium, from where they were admitted
from (community, institutional setting, or transfer) and whether discharged to comniunity
or institutional setting was determined for each patient, and disease severity. The UHC
database accounts for severity of illness and comorbid conditions variables (severity score)
using a combination of the RDRGs and the UHC Complication Profiler (UCP) which is
based on original research by Lisa Iezzoni at Beth Israel Hospital (Iezzone et al, 1992;
Kalish et al.,, 1995; Iezzone et al.,, 1994). Four levels of severity are defined: Baseline (no
substantial CCS), moderate CCS, major CCS, and catastrophic CCS (surgery).

All patients using ChEi during hospitalization were identified. The name of the
ChEi, the average dose per day and the days of cholinesterase inhibitor therapy were
determined for each patient. A flow chart describing the specific data elements collected
can be found in Appendix C.
The entire population of dementia patients was used for specific aims 1,2, and 3. It
could not be determined by looking at the data whether 1) multiple strengths of the same
drug for the same patient were given as one dose or as multiple doses or, 2) if those
patients who may have received multiple doses of a drug with different days of therapy
were being titrated up or off a medication or if there was some overlap between doses,
these individuals were excluded from the remaining analyses to avoid assumptions that
could possibly over or underestimate the calculated ACh burden score. In other words,
patients who received more than one dose strength of an ACh medication during their
hospital stay and the days of .therapy were different from each other and from observed

LOS were excluded from the analyses for specific aims 4 , 5 , 6 , 7 and 8.
Patients included for the remaining analyses (specific aims 4, 5, 6, 7, and 8) were:
1) those who received one strength only for one ACh drug, or 2) those who received more
than one ACh drug during their hospital stay and had multiple rows of data which had to
be combined into one row per patient, or 3) those patients who received different strengths
of an ACh drug but their days of therapy were the same as their observed LOS then the
doses were combined and counted as one ACh drug and the combined dose was used in
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calculating their ACh burden score. ACh burden was determined for each patient as dose
[low, medium, high] x days of therapy x ACh potency [low, medium, high] summed across
all ACh drugs. High doses were assigned a 3, medium assigned a 2, and low assigned a 1.
Doses were defined using dosing recommendations for the elderly compiled in the
Geriatric Dosage Handbook (Semla et al., 2005). Days of therapy was definded as: acute =

<2
-

days of therapy and thus assigned a 1 or chronic being >2 days of therapy and thus

assigned a 2 into the calculation. High ACh potency was assigned a 3, mediuni assigned a
2, and low ACh potency assigned a 1 for use in the above formula. ACh potency was
estimated based on comparative drug tables compiled in the Geriatric Dosage Handbook
(Semla et al., 2005) (AP, antidepressants, and antihistamines) and clinical pharmacology
data in the published literature. The dose and potency definitions are in Appendix E.
Some of the variables in the data set had too many levels and therefore had to be
condensed to fewer levels for the analyses, such as admission source had 18 levels,
discharge status had 2 1 levels, and primary diagnosis had 1352 levels and were recoded as
3,4, and 26 levels respectively. The definitions of how the variables were recoded for
theses analyses can be found in Appendix D. There were no outliers excluded from the
data analyses.

111. Data Analysis
All statistical analyses were perfomled using JMP 5.1. Assumptions of each test
were checked before tests were performed. If the assumptions were not met then
appropriate data transformations were performed. The significance level was set at 0.05.

A. Specific Aim #1
The first aim was to determine the prevalence of ACh medication use in
hospitalized elderly patients 2 65 years of age with dementia. Prevalence of ACh drug use
in patients with dementia was calculated by dividing the number of patients taking at least
one ACh drug by the total number of patients with dementia (diagnosed and inferred).
Characteristics of the groups were compared using tests of statistical significance
appropriate for each variable type (Chi-square or t-test). The observed LOS was not
normally distributed and therefore its log transformation was used for analyses and back
transformed for reporting purposes.

Prevalence of AChdementi,
=3
Total # of dementia patients

B. Specific Aim #2
The second aim was to determine ACh prevalence in hospitalized elderly patients
with dementia (Alzheimer's disease or other dementias) on ChEi. Prevalence of ACh drug
use in patients with dementia and on ChEi therapy was calculated by dividing the number
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of patients taking at least one ACh drug and a ChEi by the total number of patients taking a
ChEi.
Prevalence of ACh,

of patients on ChEi and > 1 ACh drug
Total # of dementia patients on ChEi

ChEi dementia patients = #

C. Specific Aim #3
The next aim was to compare the ACh prevalence between hospitalized elderly
patients with dementia using and not using ChEi therapy. Prevalences of hospitalized
elderly patients taking ACh (dependent categorical (Y/N) variable) with or without a ChEi
(independent categorical (Y/N) variable) were compared using 2.

D. Specific Aim #4
The fourth aim was to compare ACh burden between hospitalized elderly patients
with dementia on and not on ChEi therapy.
The independent variable is ChEi therapy and is dichotomous, the dependent
variable is ACh burden and was assessed as a continuous variable. Test for equal
variances was done first to test for significant differences between group sizes. Since there
was a significant difference, the t-test for unequal variances was used to assess the
difference between the two groups.
If ACh burden is significantly different between groups then it would be expected
that the total number of ACh drugs would also be different between groups. The total
number of ACh drugs (dependent continuous variable) with a ChEi was compared to those
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without a ChEi. Test for equal variances was done first to test for significant differences
between group sizes. Since there was a significant difference the t-test for unequal
variances was used to assess the difference between the two groups.

E. Specific Aim #5
The fifth aim was to characterize prescribing patterns of ACh medications in the
hospitalized elderly, particularly those with dementia with or with out ChEi therapy.
The percentage use for each ACh drug in each group of patients, those with or
without ChEi therapy, was calculated by dividing the number of courses of therapy for that
drug in that group of patients by the total number of courses of therapy for all ACh drugs.
A patient can have more than one course of therapy if they received more than one ACh
drug during the hospitalization. Average daily dose and average days of therapy for each
ACh drug was calculated to determine whether some medications are being used at higher
or lower doses relative to their labeled dosage range.

F. Specific Aim #6
The following aim was to compare the prescribing patterns of urinary
antispasmodics, GI antispasmodics, sedating antihistamines and antispychotics (AP)
between hospitalized elderly patients with dementia using and not using ChEi therapy.
There are two different groups being analyzed, those using or using on ChEi
therapy which is the independent dichotomous variable. Each group has the dependent
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variables of urinary antispasmodics, GI antispasmodics, and AP and each was analyzed
between groups using

2.

G. Specific Aim #7
The following aim evaluated and compared the impact of ACh medication use in
hospitalized dementia patients on LOS, discharge status, and having delirium while in the
hospital. A stepwise regression analysis was conducted to evaluate whether ACh use
(categorical: yeslno) was associated with increased LOS in elderly patients with dementia.
The dependent variable was log LOS and the independent variables evaluated were age,
sex, race (White, Black, other (Asian, Hispanic, Native ArnericanlEskimo, unknown),
severity score (baseline/moderate/major/catastrophic), admission source
(community/instit~~tion/other),
discharge status (community/institution/other/died), and

whether or not the patient was coded for delirium, received an ACh drug or received a
ChEi. Criteria for the stepwise regression were defined as the probability of F or enter 5
0.05 and probability of F to remove > 0.10.
Logistic regression analysis was used to evaluate the association between ACh
medication use and discharge status (change from community to institution) and also
whether or not the patient was documented as having delirium during their hospital stay.

H. Specific Aim #8
The last aim of the study was to evaluate and compare the impact of ACh burden in
hospitalized dementia patients on LOS, discharge status, and having delirium while in the
hospital.
For each group (ChEi with ACh and no ChEi with ACh), severity score,
documented delirium, ACh burden, admission source, discharge to community/institution/
/other setting, age, race, and sex was incorporated as covariates in the regression model.
ACh burden was assessed as a continuous independent variable for patients who received
at least one ACh drug. It is expected that increasing exposure will be associated with
increased LOS, change in discharge status between where they were admitted from and
where they were discharged to, and having delirium while in the hospital.
The independent variable ACh burden and the dependent variable LOS was
assessed as continuous variables and therefore was analyzed using a linear regression after
log transformation of LOS.
Change in status between where they were admitted fiom and where they were
discharged to was assessed as a dichotomous variable (institution, non-institution) and
therefore analyzed using logistic regression.
Whether or not the patient was documented as having delirium while in the hospital
was also assessed as a dichotomous variable and analyzed using logistic regression.

CHAPTER 4 Results

I. Specific aim #1
The first part of aim #1 was to compare characteristics between the groups and test
for significance. Table 7 shows the characteristics of the study population at admission.
There were 12,481 dementia patients with a mean age of 81.2 years, SD = 7.2 years with
60.3% of the population being female. This is representative of the elderly (265 years)
population with dementia. Eighty-four percent of the dementia population was admitted
from the community, of which 46.9% were admitted with a moderate severity score. The
most common primary diagnosis was circulatory/vascular/heart disease in the dementia
population.
The population characteristics were normally distributed. There were missing
values listed as unknown (n=68) for severity scores in the data set. There were no
significant differences in age (p = 0.9), sex (p = 0.8), race (p = 0.4), severity score (p = 0.3)
nor admission source (p = 0.6) between the four groups (no ChEi with no ACh, no ChEi
with ACh, ChEi and no ACh, or ChEi and ACh). The observed LOS was not normally
distributed and therefore its log transformation was used in analyses.

Table 7. Population characteristics

Age (years)
Mean ( 5 SD)
Sex
% Female
Race
%White
% Black
% Asian
% Hispanic
% other or unknown
Admission source:
% Community
% Institution
% other
Severity score:
% unknown
% baseline no
substantial ccs
% moderate ccs
% major ccs
% catastrophic ccs
(w%WY)
% with documented
delirium
Average LOS* (days)
(SD, [95% CI])
Primary Diagnosis (%)
common

2nd most common

-ChEi

+ChEi

General
Population
81.2
( 2 7.2)

-ACh
82.2
( 5 7.4)

+ACh
81.3
(+ 7.4)

-ACh
81.1
(26.9)

+ACh
79.9
( 2 6.9)

60.3
69.0
18.8
1.1
2.7
8.4

64.7
59.0
23.9
1.3
3.7
12.0

62.2
68.3
19.2
0.9
3.2
8.4

56.2
73.6
16.5
1.2
1.8
6.9

59.4
77.0
14.6
0.8
2.3
6.6

84.0
14.6
3.4

83.5
14.1
2.3

80.8
14.9
4.3

82.4
14.4
3.2

82.3
15.1
2.6

0.5

0.4

0.8

0.4

0.9

19.6
46.9
28.0

18.3
46.9
31.1

15.9
43.8
32.5

22.3
49.6
23.4

19.3
44.1
28.2

5.0

3.3

7.1

4.3

7.5

5.5
4.9
(2.4, [4.8-5.01)

7.3
4.1
(2.3, [4.0-4.21)

8.9
6.0
(2.4, [5.7-6.21)

3.5
4.7
(2.4, [4.5-4.81)

4.2
6.2
(2.5, [6.0-6.41)

circulatory/
vascular/ heart
dz (19.7%)

circulatory/
vascular/ heart
dz (18.1%)

circulatory/
vascular/ heart
dz (18.4%)

circulatory1
vascular1 heart
dz (21.1%)

circulatory1
vascular1 heart
dz (20.6%)

respiratory
infectioddz
(11.1Yo)

respiratory
infectioddz
(14.0%)

dementia
(1 1.3%)

respiratory
infection/dz
(10.0%)

dementia
(9.6%)

dementia
(10.1%)

dementia
(1 1.3Y0)

respiratory
infectioddz
(11.1%)

dementia
(8.8%)

mental/mood
dl0 (8.6%)

3rd most common

4th most common
gastrointestinal
disease (6.2%)
12,481

gastrointestinal
disease (8.8%)
1,601

respiratory
infectioddz
(8.1%)
2,485

fracture (5.3%)
UTI (7.4%)
total (n)
4,44 1
3,954
+=yes; - = n o
*Average LOS was calculated from the LOG transformation of LOS observed and then back transformed
dz = disease; d/o = disorder; ccs= complications & comorbidities

-

The second part of aim # 1 was to determine the prevalence of ACh medication use
in hospitalized elderly patients 2 65 years of age with dementia. There was a total of 4086
dementia patients who received at least one ACh drug during their hospitalization. The
ACh prevalence aniong all dementia patients was 4086112,481 = 32.7%. There was not a
significant difference in ACh prevalence between those admitted from an institution and
those admitted from the community.

11. Specific Aim #2
The second aim of the study was to determine ACh prevalence in hospitalized
elderly patients with dementia on ChEi therapy. There were 2485 patients on ChEi therapy
that also received at least one ACh drug. ACh prevalence in the dementia patients using
ChEi therapy was 248516926 = 35.9% and 160115555 = 28.8% for those not using ChEi
therapy.
There were a total of 7275 courses of ChEi therapy given. Table 8 shows the ChEi
utilization for those also receiving ACh drugs and those not receiving ACh drugs.

Table 8. ChEi utilization by group
-ACh
Drug
Donepezil
Galantamine
Rivastigmine
Tacrine

Frequency (%)
53.4
4.9
5.2
0.04

Average
dose (mg)
10.2
16.7
8.4
29.4

Average
therapy (days)
5.1
5.1
5.9
3

Frequency (%)
30.8
2.6
3.1
0.0

Average
dose (mg)
9.9
19.3
7.2
0.0

Average
therapy (days)
6.3
6.3
6.7
0.0

111. Specific Aim #3
The third aim was to test for significant differences in ACh prevalence between
dementia patients on ChEi therapy and dementia patients not on ChEi therapy. Table 9
shows the total number of individuals in each group and the respective proportions
receiving an ACh medication. There were 4086 dementia patients who received at least
one ACh medication during their hospital stay. The ACh prevalence was significantly
higher in the dementia patients who receive ChEi therapy than those who did not receive
ChEi therapy (chi-square 70.1, d e q , p < 0.0001).

Table 9. Proportion receiving ACh within each group

received
ChEi

count
(proportion)
No
yes
total

received ACh
No
Yes
3954 (.471) 1601 (.392)
4441 (.529) 2485 (.608)
8395 (1 .O)
4086 (1 .O)

total
5555 (.445)
6926 ( 3 5 )
12481 (1.0)

IV. Specific Aim #4
The next aim of the study was to compare ACh burden between hospitalized
elderly patients with dementia using and not using ChEi therapy. After excluding those
patients who received multiple different doses of an ACh that had different days of therapy
from each other and from the observed length of stay, there were 3486 patients remaining
of the original 4086 patients for this analysis. Table 10 shows the mean total number of
ACh drugs and ACh burden for dementia patients taking and not taking ChEi therapy.
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ACh burden was compared between ACh with ChEi and ACh with no ChEi, using
Welch ANOVA due to a significant difference between the group sizes (F(1,3 180.6) =
9.9, p = 0.0017). When using the t-test for unequal variance, ACh burden was
significantly higher (difference = 0.5,95%CI [0.2,0.8], p = 0.0017) in those patients
receiving a ChEi than those who were not receiving a ChEi.
The total number of ACh medications was compared using Welch ANOVA and
were found to be significantly different (F(1,3 176.7) = 8.9, p = 0.0029). When using the ttest for unequal variance, the total number of ACh drugs was higher in patients receiving
ChEi than those who were not (difference = 0.05,95% CI [0.02, 0.081, p = 0.0029).

Table 10. ACh medication use
mean

std dev

95% CI

1.2
7.1

0.5
4.9

1.18
6.9

1.23
7.3

1.2
6.6

0.4
4.3

1.1
6.4

1.2
6.9

dementia pts +ChEi
# ACh drugs

ACh burden
dementia pts -ChEi
# ACh drugs

ACh burden

V. Specific Aim #5

The purpose of this aim was to characterize prescribing patterns of ACh
medications used in the hospitalized elderly, particularly those with dementia with or with
out ChEi therapy. There were 55 10 ACh courses given to 3486 hospitalized elderly
patients with dementia. Table 11 shows the frequency of use for a particular ACh drug and
its average dose and days of therapy for dementia patients that did or did not receive ChEi
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therapy. The most frequently used ACh drugs were: tolterodine 4.4%, oxybutynin 6.4%,
atropine 7%, promethazine 12.2%, olanzapine 16.8%, and diphenhydramine 19.7%.
Olanzapine, tolterodine, and oxybutynin were given chronically (average days of therapy
were approximately 5 for each) and accounted for 27.6% of all prescribed ACh, whereas
atropine, promethazine and diphenhydramine were mainly given acutely (average days of
therapy were approxinlate 1.5 for each) and accounted for 38.9% of all prescribed ACh.
The average dose for most of the ACh drugs given were less than the suggested
recommended maximum dosage per the Geriatric handbook. The average
diphenhydramine dose was nearly double and average clozapine was nearly triple the
recommended maximum dosage listed in the Geriatric handbook. The average promazine
and nortriptyline doses given were also higher than the recommended maximum dosage
listed in the Geriatric handbook. The average doses of oxybutynin and tolterodine given
were slightly higher than the recommended maximum dosage listed in the Geriatric
handbook.

Table 11. ACh prescribing patterns
+ChEi
frequency
ACh Drug
Amitriptyline
Atropine
Atropine1
diphenoxylate
Atropinelhyoscyamine
1 scoplpheno
Belladonna/opium
SUPP

Ave.
dose

95% CI

Ave.
tx

-ChEi

I
1

frequency
(%)

0.6

Ave.
dose
(mdf
37.5

95% CI
(dose)
27.7, 47.3

Ave.
tx
(days)
5.3

ACh Drug
Benztropine
Chlorpromazine
Clozapine
Desipramine
Dicyclomine
Diphenhydramine

I

frequency
w )
0.8

Ave
dose
(mdt
1.5

95% CI
(dose)
1.1, 2.0

0.3

48.2

21.2, 75.2

0.1

83.1

39.6, 126.6

4.7

0.1

83.3

22.0, 144.7

3.2

0.1

28.6

19.2, 37.9

11.6

44.8

42.7, 46.9

0.02

75.0

7.6

33.3

31.5,35.1

1.6

3.1
0.1

5.8
6.9

4.4, 7.2
2.0, 29.0*

4.6
4.8

11
1

(Table 11 continued from page 49)

Ave tx
(days)
4.7

frequency
("h)
0.8

1

0.0

1.5

-ChEi
Ave
dose
(mdt
1.5

95% CI
(dose)
1.2, 1.8

77.7

43.2, 112.2

270.6

181.3, 360.0*

4.5

0.0

0.0~

0.0

21.7

10.0, 36.0*

45.4

42.8, 48.0

Ave tx
(days)
3.9

1

1.5

Doxepin
Hydroxyzine
Hyoscyamine
Imipramine
Nortriptyline
Olanzapine

I

Oxybutynin
~romazine

I Promethazine

I

1
1

75.0~

1.0

1

1

0.04

25.0

25.0~

1.0

4.6

29.7

28.2, 31.2

1.7

1.3
0.1

5.0
4.2

3.3, 6.7
0.9, 7.6

4.5
2.9

Scopolamine
Thioridazine
Tolterodine tartrate
Trihexyphendyl

dosage is in mg except where otherwise noted

* when the lower 95% CI was 0 due to their being only a few doses with wide spread, the 95% CI was entered as the minium and maximum dosages

'Ave=
there was either no doses, one dose, or two doses given at the same dose
average; tx= therapy

VI. Specific Aim #6
The purpose of this aim is to compare the prescribing patterns for the ACh classes:
urinary antispasmodics, GI antispasmodics, sedating antihistamines and ACh
antispychotics between hospitalized elderly patients with dementia on and not on ChEi

I
/
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therapy. Table 12 shows the number of patients in each group, those receiving and not
receiving ChEi therapy, that received at least one ACh dose from each ACh class. There
were no significant differences in the proportion of AP (p =0.6), GI antispasmodics
(p = 0.7), nor sedating antihistamines (p = 0.4) doses given between hospitalized dementia
patients receiving and not receiving ChEi therapy. There was a significant difference in
the proportion of urinary antispasmodics (p <0.0001) given between hospitalized dementia
patients receiving and not receiving ChEi therapy.

Table 12. Proportion receiving ACh class per group
ACh drug class
Antipsychotic
GI antispasmodic
Sedating antihistamine

-ChEi
455 (0.40)
178 (0.39)
1098 (0.52)

+ChEi
678 (0.60)
282 (0.61)
1011 (0.48)

total
1133
460
2109

Urinary antispasmodic

177 (0.30)

407 (0.70)

584

VII. Specific Aim #7
Aim #7 evaluated and compared the impact of ACh medication use in hospitalized
dementia patients on LOS, discharge status, and having delirium while in the hospital.
There were 11,881 of the original 12,481 patients for this analysis after excluding 600 who
had received multiple different ACh doses with different days of therapy from each other
and from the observed LOS. An additional 60 patients were omitted from the analyses
because of missing severity score values. Table 13 is a correlation matrix that shows the
relationships among the study variables.

Table 13. Correlations among independent and dependent variables
Age
(yrs)
Age (yrs)

1 .oo
-0.055

Race

p<ooo~

Received ACh?

-0.065
p< 0001

-0.082
Received ChEi?
Severity Score
Admission
Source

p< 0001

0.020
p= 03

Race

1.00
-0.068

Received
ACh

p< 0001

1.00

-0.14

0.069

p< 0001

p<.0001

-0.010

0.069
p<.ooo~

Received
ChEi

1.00
-0.051
p< 0001

-0.017

Severity
Score

-0.007

0.0036

p=os

-0.0043

Discharge Status

0.11

-0.031

0.026

-0.11

0.23

p< 0001

p= 002

p= 004

p< 0001

p< 0001

Log LOS obsvd

p<.ooo~

0.010

p<.mol

0.14

0.043

p< 0001

p<.ooo~

Sex
Patient coded for
delirium?

0.12

0.060

-0.017

Log
LOS
obsvd

Sex

0.28

0.0044
0.01 1

1.00
0.17

p< 0001

p< 0001

p<.oool

P<.OOOI

1.00

0.0022

-0.07

-0.036

0.0057

0.0005

-0.031

p<.ooo~

p<.ooo~

p<.ooo~

p<.ooo~

p<.ooo~

P<.OOOI

1.00

0.024

0.054

-0.023

p=.01

p<ooo~

p=.01

0.0067

p<ooo~

Patient
coded for
delirium

1.00

-0-091
0.014

Discharge
Status

1.00

-0.0009

-0.047

Admission
Source

0.013

0.0017

1.00

A. ACh impact on LOS
The results from specific aim #3 showed that there was a significant difference
between ACh use for those who receive or do not receive ChEi therapy. ANOVA was
performed to test the significance of an interaction between ChEi therapy and ACh
medication use with LOS. Since there was evidence of a non-ignorable interaction
(p=.0008), of whether or not one received an ACh or a ChEi therapy on LOS, the effect of
one factor will be considered separately for each level of the other factor. The effect of
ChEi therapy will first be considered within the two ACh groups. Within the subgroup of
patients without ACh therapy, there was a significant difference in LOS depending upon
whether they received ChEi therapy (unadjusted p<.0001, Bonferonni cut-off = .0125),
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those that received ChEi therapy had a LOS of 1.2 days longer (SE= 1.0). Within the
subgroup of patients who received an ACh there was no significant difference in LOS
depending upon whether or not they received ChEi therapy (unadjusted p=.03, Bonferonni
cut-off = .0125). Within the subgroup of patients who did not receive a ChEi there was a
significant difference in LOS depending upon whether or not they also received an ACh
drug (unadjusted p<.000 1, Bonferonni cut-off =.O 125), those that also received an ACh
had a LOS of 1.3 days longer (SE=1.0). Within the subgroup of patients who did receive a
ChEi there was a significant difference in LOS depending upon whether or not they also
received an ACh drug (unadjusted p<.000 1, Bonferonni cut-off = .0 125), those that
received an ACh had a stay of 1.1 days longer (SE=1.0).
The above results were confirmed by repeating the analysis with the independent
variable as group (no ACh with no ChEi; no ACh with ChEi; ACh with no ChEi; and ACli
with ChEi) and the groups were compared with Tukeys HSD multiple comparison.
Further analysis on the variables and the three most prevalent diagnosis on admission were
compared between subgroups to further explain these results.
Those with no ACh therapy (n=8395) with their ChEi therapy, had a significantly
longer LOS than those who did not receive ChEi therapy. Those on ChEi therapy were
significantly younger and white (p<.0001), were less likely to be coded for delirium
(p<.0001), were significantly more likely to have a severity score of 4 (catastrophic), 2
(moderate), or 1 (baseline) (p<.0001), and more likely to be discharged to either the
community or other (other, unknown, transfer). Also the proportion of men compared to
the proportion of women was significantly higher for those not on an ACh (p<.0001).

Those on a ChEi were significantly more likely to be admitted for
circulatory/vascular/heart disease (p<.0001).

In those patients who were not on ChEi therapy (n=533 1) but received at least one
ACh had a significantly longer LOS than those who did not receive an ACh. They were
also significantly younger (p=.0003), more likely to be white (p<.0001), significantly more
likely to have a severity score of 3 (major) or 4 (catastrophic) (p<.0001), and more likely
to be admitted for circulatory/vascular heart disease (p=.02). There was a significant
difference in discharge status (p=.02) depending on whether or not they were also taking
an ACh. Those on ACh were more likely to have a discharge status of 3 (other, unknown,
transfer) or 4 (expired) (p=.02), those not on ACh were more likely to be discharged to the
community, but there were no significant differences in discharge status to an institution
whether or not they received an ACh.
In those patients who were on ChEi therapy (n=6550) but received at least one ACh
had a significantly longer LOS than those who did not receive an ACh. They were also
significantly younger (p<.0001), more likely to be white (p<.01), a significantly larger
proportion were female (p<.03), and significantly more likely to have a severity code of 3
(major) or 4 (catastrophic). They was a significant difference in discharge status (p=.006)
depending on whether or not they were also taking an ACh. Those on ACh were more
likely to have a discharge status of 3 (other, unknown, transfer) or 4 (expired), those not on
ACh were more likely to be discharged to the community, but there were no significant
differences in discharge status to an institution whether or not they received an ACh.
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A dose-response relationship with ACh administration (diphenhydramine) has previously
established a significantly longer hospital stay (Agostini et al., 2005).
To further confirm the above differences between groups, stepwise multiple linear
regression was used to evaluate the impact of ACh medication use on LOS. ChEi therapy
and the ACh-ChEi interaction were put into the stepwise regression model because of its
significant interaction between the two. Independent variables entered the stepwise
regression model in the following order: severity score, discharge status, whether or not
they received an ACh, whether or not they received a ChEi, age, whether or not they coded
for delirium, race, and then the ACh-ChEi interaction. The first three variables account
for the majority of the change in the r2. Whether or not they received a ChEi and the AChChEi interaction added 0.54% and 0.08% respectively, of the variability accounted for in
the model. The model accounts for approximately 14% of the variability in LOS (r2=
0.1433) for elderly patients with dementia. The table 14 shows the median and average
LOS for each of the groups. The model summary output from JMP is in Table 15.

Table 14. LOS comparison between groups

Group

-ACh -ChEi

median
(days)
4.0

mean
(days)

5.9

95% CI
5.7

6.1

Table 15. Model summary of ACh use (YIN)with Response: LOS
Stepwise Fit
Response:
Log LOS obsvd

Stepwise Regression Control
Prob to Enter
Prob to Leave

0.050
0.100

60 rows not used due to missing values (severity score).

Current Estimates
SSE
1466.6884

DFE
11807

MSE
0.1242219

RSquare
0.1433

Entered Parameter
X
(Intercept
X
Age (yrs)
Sex 2{2-1)
X
Race2{1-2&3)
Race2{2-3)
X
X
Received ACh?{NO-YES}
X
Recieved ChEi?{NO-YES}
X
Received ACh?{NO-YES)*Recieved ChEi?{NO-YES)
X
Patient coded 4delirium?{NO-YES)
X
Severity Score 2{ 1&2-3&4)
X
Severity Score 2{1-2)
X
Severity Score 2{3-4)
Admission Source 2{1&2-3)
Admission Source 2{1-2)
X
Discharge Status 2{ 1-4&2&3)
X
Discharge Status 214-2&3)
X
Discharge Status 2{2-3)

RSquare Adj
0.1424
Estimate
1.0074885
-0.003034
0
-0.0150357
-0.009303
-0.0392774
-0.0257152
-0.0122351
-0.0424449
-0.1378355
-0.0278838
-0.1025714
0
0
-0.0441862

Cp
15.540933
nDF
1
1
1
2
2
1
1
1
1
3
3
3
2
2
3

SS
0
5.336063
0.143045
2.221552
2.221552
14.38638
5.988514
1.416281
4.269739
114.0869
114.0869
114.0869
0.414475
0.4 14475
62.72743
62.72743
62.72743

AIC
-24640.9
F Ratio
0.000
42.956
1.152
8.942
8.942
115.812
48.208
11.401
34.372
306.137
306.137
306.137
1.668
1.668
168.321
168.321
168.321

Step History
-

Step Parameter
1 I Severity Score 2{1-2)
2 Discharge Status 2{1-4&2&3)
3 Received ACh?{NO-YES)
4 Recieved ChEi?{NO-YES)
5 Age (yrs)
6 Patient coded 4delirium?{NO-YES)
7 Race2{1-2&3)
8 Received ACh?{NO-YES}*Recieved ChEi?{NO-YES)

Action

1 Entered I
Entered
Entered
Entered
Entered
Entered
Entered
Entered

"Sig Prob"
0.0000(
0.0000
0.0000
0.0000
0.0000
0.0000
0.0002
0.0007

Seq SS RSquare
148.96211 0.08701
58.00988
0.1209
15.70859
0.1301
9.253 148
0.1355
5.769217
0.1388
4.167696
0.1413
2.130845
0.1425
1.416281 0.1433

Cp
772.121
3 11.07
186.6
114.1
69.654
38.099
24.944
15.541

p
41

B. ACh impact on delirium

A chi-square of ACh drug use (Y/N) verses whether or not a patient coded for
delirium showed no significant difference (p = .47). A logistic regression was used to

Prob>F
1.0000
0.0000
0.2832
0.0001
0.0001
0.0000
0.0000
0.0007
0.0000
0.0000
0.0000
0.0000
0.1886
0.1886
0.0000
0.0000
0.0000

evaluate the impact of ACh medication use and whether or not the patient was coded for
delirium, first with ACh use alone and then including the ACh-ChEi interaction.
Even after taking into account the other variables, ACh medication use was still not
significant in whether a patient coded for delirium or not (p=.66). When analysis was
repeated taking into account ChEi use and the ACh-ChEi interaction, ACh medication use
became even more non significant in whether a patient coded for delirium or not (p=.74).
The ACh-ChEi interaction was also non-significant (p=.5 1) but ChEi use was significant
(p<.0001). ACh medication uses' lack of significance could be due to the inability from
the database to differentiate whether or not the ACh drug was being used to treat delirium,
such the case with the use of many AP or if it was causing the delirium. The lack of
significance could also be due to whether or not a patient actually gets documented as
having delirium during their hospital stay. Accurate documentation of delirium relies
heavily upon patient records and not billing codes. In the 11,881 patients used in this
analysis, only 5% of the patients were documented as having delirium, which is grossly
understated compared to numerous studies which document 14-56% (Rosin 1966;
Hodkinson 1973; Bergman 1974; Seymour 1980; Chisholm 1982).

C. ACh impact on discharge status
Chi-square indicated a significant difference (p=.05) between community-dwelling
elders discharged to either community or an institution depending on whether or not they
received an ACh drug. There is a greater likelihood of being discharged to an institution if

57
they received an ACh drug (p=.03). A logistic regression was used to evaluate the impact
of ACh medication use on discharge status, first ACh use alone and then including the
ACh-ChEi interaction.
After taking into account the other variables, ACh medication use was no longer
significant (p = .49). When the analysis was repeated to include ChEi and the ACh-ChEi
interaction, ACh medication use became even more non- significant (p = .98). The AChChEi interaction was also non-significant (p=.20), but ChEi use was significant @<.0001).

VIII. Specific Aim #8
The purpose of this last aim was to further evaluate the impact of ACh burden in
hospitalized dementia patients on LOS, discharge status, and having delirium while in the
hospital. ACh burden was slightly skewed to the left (median = 6, range [2,36]) and
therefore its log was used in the following analyses.

A. ACh burden and LOS
A stepwise multiple linear regression will be used to evaluate the impact of ACh
burden on LOS. Since it was previously shown that ACh use impacts LOS, this analysis
attempted to look at a dose response relationship in only those patients who received at
least one ACh drug. Independent variables entered the stepwise regression model in the
following order: severity score, log ACh burden score, discharge status, whether or not
they coded for delirium, age, race. The first three variables account for the majority of the

change in the r2. The model accounts for approximately 17% of the variability in LOS (r2
= 0.1701)

for elderly patients with dementia. The model summary output from JMP is in

Table 16.

Table 16. Model Summary of ACh burden with Response: LOS
Stepwise Fit
Response :
Log LOS obsvd

Stepwise Regression Control
Prob to Enter
Prob to Leave

0.050
0.100

8428 rows not used due to missing values (did not receive an ACh drug).

Current Estimates
SSE
426.78412

DFE
3440

MSE
0.1240652

RSquare
0.1701
Estimate
0.8759619 1

Lock Entered Parameter
X
X
Intercept
X
Age (yrs)
Sex{FEMALE-MALE)
Race 2{1-3&2)
X
Race 2{3-2)
X
X
Recieved ChEi?{NO-YES)
X
Patient coded 4delirium?{NO-YES)
X
Severity Score 2{1&2-3&4)
X
Severity Score 2{ 1-2)
X
Severity Score 2{3-4)
Admission Source 2{1&2-3)
Admission Source 2{ 1-2)
X
Discharge Status 2{1-2&4&3)
X
Discharge Status 2{2-4&3}
Discharge Status 2{4-3)
X
X
Logburden

RSquare Adj
0.1672
nDF
11

Cp
14.194673
SS
0

AIC
-7193.26

F Ratio
0.000 1

Step History
parameter
1 I Severity Score 2{1&2-3&4)

Action
IEntered
Entered
Entered
Entered
Entered
Entered
Entered

I

"Sig Prob"
0.0000 1

Seq SS RSquare
Cp
54.6154 1 0.1062 1 260.94 1

e

4

Prob>F
1.ooool

B. ACh burden and delirium
A chi-square of ACh burden verses whether or not a patient coded for delirium
showed no significant difference (p = .34). Even after taking into account the other
variables, ACh burden still was not significant in whether a patient was coded for delirium
ornot (p = .14).

C. ACh burden and discharge status
A logistic analysis of ACh burden (continuous variable) verses change in discharge
status (community or institution) in community dwelling elderly showed no significant
difference (p = .34). Even after taking into account the other variables, ACh burden still
was not significant in discharge status of community dwelling elderly (p = .8).

Chapter 5 Conclusions/Discussion

I. Conclusion
A. ACh prevalence

A1 . Prevalence among hospitalized elderly dementia patients
In this study, 32.7% of the hospitalized elderly patients received an ACh. This is
consistent with past studies that have looked at prevalence of ACh use in nursing home
patients. The Medicare utilization review found that 34.5% of patients were receiving
ACh drugs (Seifert et al., 1983). Another study that looked at diphenhydramine use only,
among hospitalized elderly patients found that 27% had received diplienhydramine during
their hospital stay (Agostini et al., 2005). Blazer et al., reported that nearly 60% of
nursing home residents and 23% of elderly people living in the community received drugs
with ACh activity.

A2. Prevalence among hospitalized elderly dementia patients on ChEi therapy
ACh prevalence among the dementia patients on ChEi therapy was 28.8% which is
consistent with the findings of past studies. Past studies that looked at state Medicaid
administrative data claims found 13.5% and 35.4% of patients receiving a ChEi were also
receiving an ACh drug (Slattum et al., 2001; Carnahan et al., 2004). Kogut et a1 looked at
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the prevalence of community and LTC residents (245) that were enrolled in the Rhode
Island Medicaid program who were dispensed a ChEi and a drug therapy that can impair
cognition (list of 58 drugs). Nearly 60% of those receiving a ChEi also received drug
therapy that can impair cognition (40 of the 58 drugs had ACh properties) (Kogul et al.,
2005). In a study by Carnahan et al., 35.4% of individuals of Iowa Medicaid beneficiaries

(2 50) taking ChEi were also concurrently receiving an ACh drug (Carnahan et al., 2004).
ACh drugs such as those used to treat urinary incontinence are frequently started after
initiation of ChEi therapy.

A3. Comparison between those on and not on ChEi therapy
The prevalence of ACh drug use in this study was significantly higher in those
patients who were receiving ChEi therapy compared to those who were not. Gill et al.,
found patients who were receiving ChEi therapy were 4.5% more likely to be prescribed an
ACh medication than those not on a ChEi. Community-based elderly taking ChEi are
more likely to receive an ACh and nearly one third of those taking a ChEi were also
receiving an ACh (Gill et al., 2005). In this study there were no significant differences in
ChEi therapy between those fi-om the community and those from an institution (p= .53).

B. Comparison of ACh burden between those on and not on ChEi therapy
The ACh burden was significantly higher in those patients on a ChEi compared to
those individuals who were not on ChEi therapy. Since ACh burden was higher, it was a
logical progression that the total number of ACh drugs would also be significantly higher.

This would seem to make sense since current literature suggests that it is likely to be
prescribed more than one ACh drug while on ChEi therapy. The total number of ACh
drugs received by an individual on ChEi therapy was significantly higher than those

,

patients not on ChEi therapy (p =.0029). The study by Roe et al., that looked at
community-dwelling elderly, pharmacy benefit management claims, of the 33% that were
receiving an ACh, 26 % of them were also taking more than one ACh drug (Roe et al.,
2002).

C. ACh prescribing patterns
Olanzapine, tolterodine, and oxybutynin were given chronically (average days of
therapy were approximately 5 for each) and accounted for 27.6% of all prescribed ACh,
whereas atropine, promethazine and diphenhydramine were mainly given acutely (average
days of therapy were approximate 1.5 for each) and accounted for 38.9% of all prescribed
ACh. The most commonly used ACh drugs were the ones used for acute or prophylactic
therapy, promethazine and diphenhydramine together accounted for 32%,
diphenhydramine alone was almost 20% of all ACh prescribed. This is not surprising and
is similar to the similar results as Beers et al., and Agostini et al., In an outpatient study of
elderly patients of intermediate-care facilities in Massachusetts, more than 25% of them
received some form of a sedative andlor hypnotic medication, with diphenhydramine
accounting for 26% (14-4 1% over all study sites) (Beers et al., 1988). In a study of
hospitalized medical patients 70 years and older, 27% had received diphenhydramine
during their hospitalization (Agostini et al., 2005).
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There were no significant differences in the proportion of AP, GI antispasmodics
nor sedating antihistamine use between those on and not on ChEi therapy, but there was a
significant difference in the proportion of urinary antispasmodics that were prescribed
between the two groups. Those receiving ChEi were significantly more likely to also
receive a drug for urinary incontinence (oxybutynin or tolterodine). Use of cholinesterase
inhibitors has been associated with an increased risk of receiving an ACh drug to manage
urinary symptoms (Gill et a1 2005; Roe et al., 2002).

D. ACh impact on LOS, delirium, and discharge status
D l . LOS
Since ACh and ChEi did not have independent effects, their separate effects on
LOS could not be distinguished. When comparing the groups (no ACh with no ChEi, no
ACh with ChEi, ACh with no ChEi, and ACh with ChEi) there was a significant difference
in LOS across groups. There was not a significant difference in LOS in the subgroup of
people taking an ACh with or without ChEi therapy. When put into order of group by its
effects on LOS in equation form it looks like this:

(ChEi with ACh) = (no ChEi with ACh) > (no ACh with ChEi) > (no ACh and no ChEi)

When multiple regression was performed the variables that had the greatest
significant effect on LOS were severity scores, discharge status, whether or not they were
taking an ACh, age and delirium and accounted for 15% of the variablity. The low

variability of the results observed could be due to a number of things. Many of the
variables and response variables were significantly correlated with each other as per Table
13. There is a significant interaction of ACh and ChEi drug use and also the fact that this
model only took into account the variables for which data was collected on and not all
variables that could possibly affect LOS.
There was a significant difference in LOS between patients who did or did not
experience delirium during their hospital stay (p<.0001), those that experienced delirium
had a significantly longer LOS than those who did not. There was also a significant
difference in LOS depending on where a patient was discharged to.

D2. Delirium
In this study it was found that only 5% of the population was documented as having
delirium, which is grossly understated and could explain why no significant difference was
found between ACh drug use nor ACh burden and whether or not a patient was coded for
having delirium during their hospital stay. There have been numerous studies which have
documented the occurrence of delirium in 14-56% of hospitalized elderly patients (Rosin
1966; Hodkinson 1973; Bergman 1974; Seymour 1980; Chisholm 1982). One reason for
the under documentation of delirium is that documentation of (Y/N) delirum relied on
patient records and not a billing code.
The inability to discern a direct relationship of ACh use or burden to delirium could
be due to a number of things. The method used to measure ACh burden most likely was
not sensitive enough. There was a case-control study (Marcantonio et al., 1994), a
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prospective study (Francis et al., 1990) and a cohort analytic study (Schor et al., 1992) that
were also unable to find a direct relationship between ACh use and delirium. These
studies documented delirium based on the patient meeting CAM, DSM-111, with or without
MMSE criteria and ACh use by either counting total number of doses received or noting
whether or not the patient received an ACh drug. There have been 14 studies that have
found a significant relationship between ACh drug use and the development of delirium all
used either SAA, plasma ACh activity, or multiplying the atropine equivalents of the drug
by the total daily dosage given and then summing them all for each ACh drug given to
measure ACh burden. They also used at least one of several tests (Delirium symptom
interview, battery of mental or psychological tests, DSM-111, CAM, or Cognitive
performance scale) in documenting delirium.

D3. Discharge status
ACh use alone was significant in determining discharge status of communitydwelling elders to either community or an institution, but when other variables where taken
into account, ACh use lost its significance. The ACh burden calculation was also found to
be non-significant in determining discharge status. This could also possibly be due to
many of the variables and response variables being significantly correlated with each other
as per Table 13. Significant differences existed between those discharged to a community
and those either discharged to an institution, other, or expired (p<.0001). There was also a
significant difference between whether or not an individual experienced delirium and
where they were discharged to (p<.0001). Those that did not experience delirium were

more likely to be discharged to the community or expired compared to those that
experienced delirium who were more likely to be discharged to either an institution or
other.

11. Limitations
This study used data that was collected from large teaching hospitals, which may
not reflect the prescribing patterns of community hospital doctors.
Another limitation is in the ACh burden calculation by defining duration of therapy
as either acute or chronic. The way acute (52 days) and chronic (>2 days) use was defined
is arbitrary. From the data set it cannot be differentiated when the doses were given. For
example, if someone received more than one dose and the days of therapy were less than
their observed LOS, one cannot tell if those doses were given consecutively or if they were
days apart. Another limitation of how the burden score was calculated is in summing the
scores of each ACh drug received by a patient. The summing assumes that two drugs each
with a rating of two would be equally ACh to one drug with a rating of 4. It is unknown if
taking multiple ACh drugs if each drug's effect is additive or if there is a certain threshold
and once that point is met the addition of anymore drugs will not exert any additional
effect or if it could exert an exaggerated effect, the relationship could be synergistic. The
calculation may have been more accurate if the dose was multiplied by atropine
equivalents but that data was only available on four of the 3 1 drugs in the literature.
Another limitation is the poorly documentation of delirium. Because it is a
database study, it cannot be distinguished when the ACh drug was given in relation to
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when the patient developed delirium. It is not possible to differentiate whether or not the
ACh drug was used to treat delirium, such as the case with the use of many AP, or if it was
causing the delirium. Also, because this is an observational study it cannot establish
causation.

111. Discussion:
Use of cholinesterase inhibitors has been associated with an increased risk of
receiving an ACh drug to manage urinary symptoms (Gill et a1 2005; Roe et al., 2002).
Multiple studies have found that approximately 33% of those on ChEi are also receiving an
ACh. Not only are those on ChEi at an increased risk (Gill et al., 2005) of being
prescribed an ACh, it is common to find them on more than one ACh drug (Roe et al.,
2002).
Medications have been implicated in at least 40% of delirium cases in hospitalized
elderly patients (Francis et al., 1990). Time and time again, numerous studies have
associated delirium with significantly increased adverse outcomes such as mortality,
significantly increased LOS, institutionalization, and functional disability (Thomas et al.,
1988; Francis et a1 1990, 1992; Levkoff et al., 1992; Inouye et al., 1993; Murray et al.,
1993; Rockwood 1993), which are significant human and economic burdens.
Carnahan et a1 found that nearly 75% of all ACh prescribed were inappropriate for
use in the elderly and of those 22% were inappropriate under any circumstance (Carnahan
et a1 2004). Another study by Agostini documented nearly 24% of all diphenhydramine
doses given to hospitalized elderly patients as inappropriate (Agostini et al., 2005).

Inappropriate use was defined as given as transfusion prophylaxis without prior
documentation of having a previous reaction or given to individuals with obstructive
urinary symptoms. In this study nearly 39% of all ACh drugs were given acutely and 32%
of them given were diphenhydramine alone.
There has only been one study conducted that looked at the prevalence of one ACh,
diphenhydramine, use in hospitalized elderly patients, in one hospital and its effects on
LOS and delirium. In that study, Agostini et al., found that the diphenhydramine exposed
group was at an increased risk for delirium, urinary catheter placement, and longer median
LOS. The dose-response relationship demonstrated a significant trend toward increased
cognitive decline and delirium symptoms with increasing dose.
The majority of studies that looked at the prevalence of concomitant use of ChEi
therapy and ACh have been done with Medicaid administrative claims, which were
performed before Medicaid Part D, may not be fully representative of this population.
This study looked at billing data that was acquired from the UHC database which includes
data from the 42 participating teaching hospitals.
Thus far this is the first study to examine the ACh prevalence of more than one
ACh drug (3 1 total), in hospitalized elderly dementia patients, diagnosed or inferred, that
are or are not concurrently taking ChEi therapy. It is also the first to study the relationship
between ACh use and burden in this population with adverse outcomes of longer
hospitalization, development of delirium, and change in discharge status from community
to an institution.

What can be taken away from this study and added to the literature: ACh are
commonly used in hospitalized elderly dementia patients in general (32.7%) and more
specifically in those elderly dementia patients who are also concurrently taking ChEi
therapy (35.9%). Those on a ChEi are more likely to receive an ACh. The most common
ACh prescribed was for the treatment of urinary incontinence, a noted side effect of ChEi
therapy. Oxybutynin and tolterodine were the two urinary antispasmodics that were
frequently used in this population, accounting for nearly 11% of ACh use. The total
number of ACh drugs and the ACh burden were significantly higher in elderly dementia
patients on ChEi therapy. Of all ACh drugs given, 39% of them were given as one or two
doses and 32% of them were diphenhydramine use, which usually means they were most
likely given prophylactically and therefore does not need to be given. Diphenhydramine is
routinely given for transfusion prophylaxis without a prior reaction documented. Also, the
practice of administering diphenhydramine prophylactically without prior transfusion
reaction has no documented benefit and should be avoided.
ACh and ChEi drug use seem to be strongly correlated with each other. There is a
significant difference in LOS between those who experience delirium and those that do not
(p<.0001). There was also a significant difference on where one was discharged to
depending on whether or not they experienced delirium (p<.0001). Those that did not
experience delirium were more likely to be discharge to either community or expired and
those that did experience delirium were more likely to be discharged to either an institution
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or other. ChEi therapy seems to have an effect on whether a patient experiences delirium
and where they are discharged to.
There have been case reports of elderly individuals with a CNS compromisii~g
condition treated with oxybutynin (MI selective) and tolterodine (non-selective
antimuscarinc) developing hallucinations, confusion, and delirium. A preferred treatment
option would be an agent that is M3 specific which have been shown to have no apparent
impact on a wide variety of cognitive function tests or to try other methods first. A recent
study showed that behavioural strategies (bladder retraining) assisted by biofeedback
which has been shown to be more effective and acceptable than oxybutynin treatment in
women with urge and mixed incontinence (Burgio et al., 1998).
Behavioral and psychotic symptoms are very common among AD patients and
have been reported in more than 80% of subjects in most studies. They are frequently
treated with AP, mood stabilizers, and antidepressants (Mega et al., 1996; Stoppe et al.,
1999). TCA and AP like olanzapine should be avoided; AP with less ACh activity (e.g.
risperidone) may be preferred in a population with dementia (Stoppe et al., 1999).
In addition, cholinesterase inhibitor therapy is associated with significant cost for
AD patients. ChEi and ACh drugs have opposing actions, and concomitant use of ACh
drugs may therefore reduce the benefits of ChEi therapy. Giving other medications that
block or counteract the potential benefits of this therapy make those costs an unnecessary
burden on the family and the health care system as a whole.
ACh use does not come without considerable cost to families and the health care
system with its associated increased LOS, delirium, risk of being transferred to an
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instituition, and mortality. Although some ACh use may be unavoidable in patients with
dementia, alternatives with minimal or no ACh activity should be considered first. Careful
consideration for potential adverse outcomes in a population that is already at high risk
based on age, baseline cognitive impairment, and other medical comorbities needs to be
taken into consideration when prescribing drugs for the treatment of some of the conditions
that commonly accompany AD.
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APPENDIX A
Defining dementia patients
ICD-9 codes

I

Delirium

331.1
331.2
290.1 1
290.3
290.41
292.81
293.0
293.1

Drugs to treat dementia
Cholinesterase inhibitors:
Donepezil
Rivastigmine
Galantamine
Tacrine

NMDA Antagonists:
Memantine

Pick's disease
Senile degeneration of brain
Presenile dementia with delirium
Senile dementia with delirium
Atherosclerotic dementia with delirium
Drug-induced delirium
Acute delirium
Subacute delirium

Appendix B
Centrally-acting drugs with ACh properties
Antihistamines:
Diphenhydramine
Hydroxyzine
Promethazine
Antiparkinson Agents:
Benztropine
Trihexyphenidyl
Antipsychotics:
Chlorpromazine
Clozapine
Olanzapine
Promazine
Thioridazine
Antispasmotics:
Atropine
Belladonna alkaloids
Belladonna L-alkaloids
Dicyclomine
Dicyclomine/Phenobarbital
Hyoscyamine
Scopolamine
Urinary antispasmodics:
Oxybutynin
Tolterodine
TCA/TCA Combinations:
Amitriptyline
Amitriptyline/chlordiazepoxide
Amitriptylinelperphenazine
Desipramine
Doxepin
Imipramine
Nortriptyline

APPENDIX C
Specific Data Elements

Stored UHC clinical
data for most recent
two quarters (total
population 2 65)

+

Stop

NO
Total number of dementia patients
Number of patients taking AChic drug
For each patient:
o Age
o Sex
o Admitting diagnosis
o LOS
o Delirium?
o Severity score
o DIC toNH?
o Where admitted from?

Dementia diagnosis or
dementia drugs during
hospitalization?

g
Dementia patient

ACh use

I4

1

Total number of dementia patients
Number of patients taking AChic drug
For each patient:
o Age
o Sex
o Admitting diagnosis
0 LOS
o Delirium?
o Severity score
o D/C to NH?
o Where admitted from?

1
ChEi therapy
during
hospitalization?

ChEi therapy
during
hospitalization?

NO
Total number of patients
Number of patients taking
AChic drug
ChEi drug name, doselday,
days of therapy
For each patient:
o Age
o Sex
o LOS
o AChic drug use
(drug name, doselday,
days of therapy)
o ACh burden
o Delirium?
o Severity score
o DIC to NH?
o Admitted from?

Total number of patients
Number of patients taking
AChic drug
ChEi drug name, dosetday,
days of therapy
For each patient:
o Age
o Sex
0
LOS
o AChic drug use
(drug name, doselday,
days of therapy)
o ACh burden
o Delirium?
o Severity score
o DIC toNH?
o Admitted from?

Total number of patients
Number of patients taking
AChic drug
ChEi drug name, doselday,
days of therapy
For each patient:
o Age
o Sex
o LOS
o AChic drug use
(drug name, doselday,
days of therapy)
o ACh burden
o Delirium?
o Severity score
o DIC to NH?
o Admitted from?

YES
Total number of patients
Number of patients taking
AChic drug
ChEi drug name, dosetday,
days of therapy
For each patient:
o Age
o Sex
o LOS
o AChic drug use
(drug name, doselday,
days of therapy)
o ACh burden
o Delirium?
o Severity score
o DIC toNH?
o Admitted from?

Appendix D
Coding Definitions

Race
11 = White
2 = Black
3 = Asian, Hispanic, Native American/Eskimo, unknown, other
Admission Source
1= Community
Physician referral
Clinic referral
ER
Home Health referral
CourtLaw enforcement
HMO referral
From Ambulatory surgery
Routine

2 = Institution
SNF (Skilled Nursing Facility)
Rehab center
Psych center
Alternative care facility
Critical access hospital
Intermediate care
Short-term acute care

3= Other
unknown
transfer
newborn

Discharge status
1= Community
2 = Institution
Discharged
Hospiclmed facility
Discharged home
LTC hosp
Home w/HHC
SNF
Home wlIV
Psych center
Hospicelhome
Rehab center
1
Left AMA
Federal hosp
Other institution for outpatient
ICF
This institution for outpatien
Acute care facility

3 = Other
4 = Died
Transferred
Expired
Other
Expired autopsy
Expired no autopsy

Primary Diagnosis (Based on ICD-9 codes)
DM (250-25 1)
Respiratory diseaselinfection (460-5 19)
Blood d/o (280-289)
Cancer (140-209)
UTI (599)
Respiratorylchest symptoms (786)
Infection (001-139,440,785)
Dementia (290-294,33 1)
Gastrointestinal disease (520-579)
Injury (830-957,990-995)
Procedurelaftercare (V50-V59)
Endocrine gland disorders (240-255)
Genitourinary disease (580-629)
Poisoning (960-979)
Mentallmood d/o (290-3 19)
Malnutrition (260-279, 783)
Fracture (800-829)
Electrolytelfluid imbalance (276)
Muscularskeletal/connective tissue diseases (710-739)
Skin/subcutaneous tissue disease (680-709)
Symptomslunk causes of morbity & mortality (799)
Circulatory/vascular/heart disease (390-459)
SignsISymptoms of ill-defined conditions (780-799)
Complications of medicallsurgical care (996-999)
Other (V60-V85,210-229,320-324,742-75 1,790)
Disease of Nervous System (320-389, excluding Alzheimer's Disease)

APPENDIX E
Anticholinergic Medications: Dose & Potency definitions

Drug #

Drug

1
2
3
4
5

amitriptyline
amitriptylinelchlordiazepoxide
amitriptylinelperphenazine
atropine (gastrointest)
atropine sulfateldiphenoxylate
6 atropine sulfateledrophonium chloride
7 atropine/hyoscyamine/scopolan~ine/phenobarbital
8 belladonna alkaloidslergotamine tartratelphenobarb
S belladonna alkaloidslopium B&O sup
10 benztropine
11 chlorpromazine
12 clozapine
13 desipramine
14 dicyclomine
15 diphenhydramine
16 doxepin
l i hydroxyzine
18 hyoscyamine
IS hyoscyaminelmethenamine mandelate
2C imipramine
2 1 nortriptyline
21 olanzapine
23 olanzapinelfluoxetine
24 oxybutynin
25 promazine
26 promethazine
27 promethazine and combos
28 scopolamine (gastrointest)
25 thioridazine
3C tolterodine tartrate
3 1 trihexyphenidyl

Low;

2= Medium; 3= High

n1g
ea
mg
ea
ea
ea

Img

I
Img
Img
Img
mg

I

1

I

Dose
2

Potency
1

3
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